WO2013110818A2 - Immunogens for hiv vaccination - Google Patents

Immunogens for hiv vaccination Download PDF

Info

Publication number
WO2013110818A2
WO2013110818A2 PCT/EP2013/051596 EP2013051596W WO2013110818A2 WO 2013110818 A2 WO2013110818 A2 WO 2013110818A2 EP 2013051596 W EP2013051596 W EP 2013051596W WO 2013110818 A2 WO2013110818 A2 WO 2013110818A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
sequence
nucleic acid
virus
seq
Prior art date
Application number
PCT/EP2013/051596
Other languages
French (fr)
Other versions
WO2013110818A3 (en
Inventor
Christian Brander
Beatriz Mothe Pujadas
Anuska Llano
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Fundació Privada Institut De Recerca De La Sida - Caixa
Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/374,334 priority Critical patent/US9988425B2/en
Priority to EP13701288.6A priority patent/EP2807185B1/en
Priority to RU2014135053A priority patent/RU2648791C2/en
Priority to NZ628756A priority patent/NZ628756A/en
Priority to KR1020147023946A priority patent/KR102108149B1/en
Priority to IN6164DEN2014 priority patent/IN2014DN06164A/en
Priority to JP2014553750A priority patent/JP6306514B2/en
Priority to CA2862172A priority patent/CA2862172C/en
Priority to EP22195110.6A priority patent/EP4163290A1/en
Priority to AU2013213564A priority patent/AU2013213564B2/en
Priority to CN201380006995.6A priority patent/CN104080800B/en
Priority to BR112014018396-1A priority patent/BR112014018396B1/en
Application filed by Laboratorios Del Dr. Esteve, S.A., Fundació Privada Institut De Recerca De La Sida - Caixa, Institució Catalana De Recerca I Estudis Avançats filed Critical Laboratorios Del Dr. Esteve, S.A.
Priority to ES13701288T priority patent/ES2932407T3/en
Priority to KR1020197018840A priority patent/KR102140778B1/en
Priority to MX2014009091A priority patent/MX358711B/en
Publication of WO2013110818A2 publication Critical patent/WO2013110818A2/en
Publication of WO2013110818A3 publication Critical patent/WO2013110818A3/en
Priority to ZA2014/05204A priority patent/ZA201405204B/en
Priority to IL233771A priority patent/IL233771B/en
Priority to HK15105237.5A priority patent/HK1204632A1/en
Priority to US15/718,635 priority patent/US10815278B2/en
Priority to US15/970,216 priority patent/US11325946B2/en
Priority to AU2018203264A priority patent/AU2018203264B2/en
Priority to IL268629A priority patent/IL268629B/en
Priority to US17/244,042 priority patent/US11919926B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom. It also relates to isolated nucleic acids expressing these immunogens as well as vectors and cells comprising such nucleic acids.
  • the compounds of the present invention are useful as vaccines, particularly for the prevention and treatment of AIDS and opportunistic diseases.
  • HIV infection induces strong and broadly directed, HLA class I restricted T cell responses for which specific epitopes and restricting HLA alleles have been implicated in the relative in vivo control.
  • HLA class I restricted T cell responses for which specific epitopes and restricting HLA alleles have been implicated in the relative in vivo control.
  • Brander C et al, Current Opinion Immunol. 2006; 18: 1-8.
  • HLA-B restricted While the bulk of the anti-viral CTL response appears to be HLA-B restricted, the relative contribution of targeted viral regions and restricting HLA molecules on the effectiveness of these responses remains obscure.
  • T cell receptor TCR
  • T cell responses to HIV Gag have most consistently been associated with reduced viral loads in both, HIV clade B and clade C infected cohorts. See Zuniga R, et al, J. Virol. 2006; 80:3122-3125 and Kiepiela P, et al, Nat. Med. 2007; 13:46-53.
  • the invention relates to an immunogenic polypeptide having an amino acid sequence comprising the sequences SEQ ID NOs 1-16 or variants of said SEQ ID NO: 1-16, wherein each of said variants has a length of at least 8 amino acids, with the provisos that said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or the variants thereof.
  • the invention relates to an immunogenic polypeptide having an amino acid sequence comprising at least one sequence selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof wherein said variant has a length of at least 8 amino acids, with the provisos that:
  • said immunogen amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or a variant or a fragment thereof, and
  • the immunogen comprises only one sequence selected from the group consisting of SEQ ID NOs 1-16, then this sequence is not selected from the group consisting of SEQ ID NO: 3, 5, 6 and 16.
  • the invention relates to nucleic acids encoding for the immunogens of the first aspect and second aspects, and to expression cassettes, vectors, a viruses and cells comprising said nucleic acids.
  • the present invention relates to a vaccine comprising an immunogenic polypeptide according to any of claims 1 to 11 and one or more adjuvants.
  • the present invention relates to the immunogenic polypeptide, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect, or the composition vaccine for use in medicine.
  • the present invention relates to the immunogenic polypeptide, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect, or the composition vaccine for use in the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
  • the present invention relates to a kit comprising the immunogen of the first and/or second aspects, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect, or the composition of the fourth aspect.
  • the plasmid 298H GMC SF-HI VAC AT DNA was deposited on January 13 th , 2012, under accession number DSM 25555 at the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen, InhoffenstraBe 7 B, D-38124 Braunschweig, Federal Republic of Germany.
  • Figure 1 Schematic representation of the gene included in the expression plasmid. Dots identify start and stop codons.
  • FIG. 1 Cellular immune responses analyzed in pooled splenocytes by flow cytometric analysis. Frequency of total Gag, Pol, and Nef-Tat-Vif specific interferon gamma responses among groups in (a) and distribution of CD4 and CD8 responses in (b) are shown.
  • FIG. 3 Responses to Gag, Pol, NTV and the HIVACAT T cell immunogen sequence measured by interferon gamma ELISpot assay in murine splenocytes.
  • the individual mice were immunized with the plasmids encoding for the full Gag, Pol and Nef-Tat-Vif polypeptide. Contribution of the responses targeting the regions included in the HIVACAT T cell immunogen to the total interferon gamma Gag-Pol-NTV specific response is shown.
  • FIG. 4 Comparison of the breadth in (a) and magnitude in (b) of the interferon gamma responses targeting the HIVACAT T cell immunogen in immunized mice. The subjects were treated with either the plasmids encoding the full proteins or the minimal T cell sequence.
  • Figure 6 Binding antibodies to p24, p37 and p55 detected by Western immunoblot by using cell extracts from HEK 293 cells transfected with the lmg of gag and gag-pol expression vectors (showing p55 gag, and processed p24, p37 and p55 gag subunits) separated on 12% SDS-Page and probing the membranes with a) human sera of and HIV-infected patient, b) pooled sera from mice immunized with high doses of the immunogen and c) pooled sera from mice immunized with low doses of the immunogen (all at a 1 : 100 dilution).
  • Figure 7 a) Endpoint titers of Gag-p24 specific binding antibody from treated mice. The determination was performed by ELISA from individual serial 4-fold diluted pooled serum samples, b) In house developed gag p55 ELISA using the HIV-1IIIB pr55 Gag recombinant protein (Cat. No. 3276, NIH Reagent Program, Bethesda, MD, US). The determination was performed in individual mice sera at 1 : 100 dilution.
  • Figure 8. a) Schematic representation of mice immunizations. Groups of six
  • C57BL/6 mice were used to compare immunogenicity of the different heterologous combinations (2xDNA prime vs 3xDNA prime followed by IxMVA boost) using either 100 ⁇ g of pDNA-HIVACAT or 10 ⁇ 6 pfu of MVA-HIVACAT by intramuscular injection, b) Comparison of the breadth and magnitude of the ⁇ responses targeting HIVACAT T cell immunogen in individual immunized mice, c) Distribution of Gag, Pol,Vif and Nef specific responses in individual immunized mice, d) Distribution among the 8 protein subunits included in the HIVACAT T cell immunogen (Gag pi 7, Gag p24, Gag p2p7plp6, Pol-Protease, Pol-RT, Pol-Integrase, Vif and Nef) in different immunization groups is shown.
  • the invention discloses several immunogenic compounds effective for inducing a high immune response against HIV in a broad range of subjects.
  • HIV-specific CD4 + and CD8 + T cell responses to key HIV-encoded epitopes have been obtained with these compounds.
  • adjuvant refers to an immunological agent that modifies the effect of an immunogen, while having few if any direct effects when administered by itself. It is often included in vaccines to enhance the recipient's immune response to a supplied antigen, while keeping the injected foreign material to a minimum. Adjuvants are added to vaccines to stimulate the immune system's response to the target antigen, but do not in themselves confer immunity.
  • Non-limiting examples of useful adjuvants include mineral salts, polynucleotides, polyarginines, ISCOMs, saponins, monophosphoryl lipid A, imiquimod, CCR-5 inhibitors, toxins, polyphosphazenes, cytokines, immunoregulatory proteins, immunostimulatory fusion proteins, co-stimulatory molecules, and combinations thereof.
  • Mineral salts include, but are not limited to, AIK(S0 4 ) 2 . AlNa(S0 4 ) 2 , A1NH(S0 4 ) 2 , silica, alum, Al(OH) 3 , Ca 3 (P0 4 ) 2 , kaolin, or carbon.
  • Useful immunostimulatory polynucleotides include, but are not limited to, CpG oligonucleotides with or without immune stimulating complexes (ISCOMs), CpG oligonucleotides with or without polyarginine, poly IC or poly AU acids.
  • Toxins include cholera toxin.
  • Saponins include, but are not limited to, QS21, QS17 or QS7.
  • An example of a useful immunostimulatory fusion protein is the fusion protein of IL-2 with the Fc fragment of immunoglobulin.
  • Useful immunoregulatory molecules include, but are not limited to, CD40L and CD la ligand.
  • Cytokines useful as adjuvants include, but are not limited to, IL-1, IL-2, IL-4, GMCSF, IL-12, IL-15, IGF-1, IFN-a, IFN- ⁇ , and interferon gamma.
  • examples of are muramyl dipeptides, N- acetyl-muramyl-L-threonyl-D-isoglutamine (thr-DMP), N-acetyl-nornuramyl-L-alanyl- D-isoglutamine (CGP 11687, also referred to as nor-MDP), N-acetylmuramyul-L- alanyl-D-isoglutaminyl-L-alanine-2-(l '2'-dipalmitoyl-sn-glycero-3- hydroxphosphoryloxy)-ethylamine (CGP 19835 A, also referred to as MTP- PE), RIBI (MPL+TDM+CWS) in a 2 percent squalene/TWEEN® 80 emulsion, lipopolysaccharides and its various derivatives, including lipid A, Freund's Complete Adjuvant (FCA), Freund's Incomplete Adjuvants, Merck
  • AIDS refers to the symptomatic phase of HIV infection, and includes both Acquired Immune Deficiency Syndrome (commonly known as AIDS) and "ARC,” or AIDS-Related Complex. See Adler M, et al, Brit. Med. J. 1987; 294: 1145-1147.
  • the immunological and clinical manifestations of AIDS are well known in the art and include, for example, opportunistic infections and cancers resulting from immune deficiency.
  • amino acid linker refers to an amino acid sequence other than that appearing at a particular position in the natural protein and is generally designed to be flexible or to interpose a structure, such as an a-helix, between two protein moieties.
  • a linker is also referred to as a spacer.
  • the linker is typically non- antigenic and can be of essentially any length (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acids).
  • the linker may also be a location or sequence where the cellular antigen processing machinery can initiate the degradation of the immunogenic polypeptide without destroying potent T cell epitopes).
  • antiretroviral resistance mutation site relates to a site that, when mutated, confers resistance to an antiretroviral agent.
  • sites can be identified by mining known databases such as the Stanford University HIV Drug Resistance Database, where, for example, sequences and treatments from viruses with specific mutations or drug susceptibility data for isolates with selected mutations can be retrieved.
  • center-of-tree sequence refers to a sequence from which the average evolutionary distance to each tip of a phylogenetic diagram of related variant sequences has been minimized. See Nickle D, et al, Science 2003; 299, 1515-1517.
  • codon optimized relates to the alteration of codons in nucleic acid molecules to reflect the typical codon usage of the host organism without altering the polypeptide encoded by the DNA, to improve expression.
  • a plethora of methods and software tools for codon optimization have been reported previously. See Narum D, et al, Infect. Immun. 2001; 69(12):7250-7253, Outchkourov N, et al, Protein Expr. Purif. 2002; 24(l): 18-24, Feng L, et al, Biochemistry 2000; 39(50): 15399-15409, and Humphreys D, et al, Protein Expr. Purif. 2000; 20(2):252-2.
  • the expression "disease associated with a HIV infection”, as used herein, includes a state in which the subject has developed AIDS, but also includes a state in which the subject infected with HIV has not shown any sign or symptom of the disease.
  • the vaccine of the invention when administered to a subject that has no clinical signs of the infection can have a preventive activity, since they can prevent the onset of the disease.
  • the immunogenic compositions are capable of preventing or slowing the infection and destruction of healthy CD4+ T cells in such a subject.
  • Beneficial or desired clinical results include, but are not limited to, an increase in absolute naive CD4+ T cell count (range 10-3520), an increase in the percentage of CD4+ T cell over total circulating immune cells (range 1-50 percent), and/or an increase in CD4+ T cell count as a percentage of normal CD4+ T cell count in an uninfected subject (range 1-161 percent).
  • variant or fragment refer to a polypeptide derived from any of SEQ ID NOs 1-16 by deletion of one or more terminal amino acids at the N-terminus or at the C-terminus of an individual SEQ ID NO.
  • Variant or fragments preferably have a length of at least 8 amino acids or up to 10%, up to 20%>, up to 30%>, up to 40%, up to 50%, up to 60%, up to 70%, up to 80%, up to 90%, or up to 99% of its respective SEQ ID NO.
  • HIV genome refers to a RNA sequence approximately 8749 nucleotide long enclosed by the HIV capsid and encoding the genes gag, pol, env, tat, rev, vif, nef, vpr, vpu, vpx, and optionally, tev.
  • the HIV genome sequence underlies high variability, for this reason, the HIV genome referred to in the invention is not limited to any specific sequence.
  • Preferred sequences are those of the HIV types and subtypes recited herein.
  • human immunodeficiency virus or "HIV”, as used herein, refer human immunodeficiency viruses generically and includes HIV type 1 ("HIV-l”), HIV type 2 (“HIV-2”) or other HIV viruses, including, for example, the HIV-l, HIV-2, emerging HIV and other HIV subtypes and HIV variants, such as widely dispersed or geographically isolated variants and simian immunodeficiency virus (“SIV").
  • HIV-l HIV type 1
  • HIV-2 HIV type 2
  • SIV simian immunodeficiency virus
  • an ancestral viral gene sequence can be determined for the env and gag genes of HIV-l, such as for HIV-l subtypes A, B, C, D, E, F, G, H, J, and K, and intersubtype recombinants such as AG, AGI, and for groups M, N, O or for HIV-2 viruses or HIV-2 subtypes A or B.
  • HIV-l, HIV-2 and SIV include, but are not limited to, extracellular virus particles and the forms of the viruses associated with their respective infected cells.
  • the "humoral immune response”, as used herein, describes an immune response against foreign antigen(s) that is mediated by antibodies produced by B cells.
  • immunogenic composition refers to a composition that elicits an immune response that produces antibodies or cell-mediated immune responses against a specific immunogen.
  • immunogenic polypeptide or “immunogen”, as used herein, refers to a polypeptide antigen that is able to induce an adaptive immune response (i.e. a humoral or cell-mediated immune response), if injected on its own or with an adjuvant.
  • kit refers to a combination of articles that facilitate a process, method or application. These kits provide the materials necessary for carrying out the application described in the present invention.
  • operably linked is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). See Auer H, Nature Biotechnol. 2006; 24: 41-43.
  • peptide tag refers to a peptide or amino acid sequence, which can be used in the isolation or purification of said immunogen.
  • said tag is capable of binding to one or more ligands, for example, one or more ligands of an affinity matrix such as a chromatography support or bead with high affinity.
  • tags useful for isolating or purifying a protein include Arg-tag, FLAG-tag, His-tag, or Strep-tag; an epitope capable of being recognized by an antibody, such as c-myc-tag (recognized by an anti-c-myc antibody), SBP-tag, S-tag, calmodulin binding peptide, cellulose binding domain, chitin binding domain, glutathione S-transferase-tag, maltose binding protein, NusA, TrxA, DsbA or Avi-tag; an amino acid sequence, such as AHGHRP (SEQ ID NO:53), PIHDHDHPHLVIHS (SEQ ID NO:54), or GMTCXXC (SEQ ID NO:55); or ⁇ - galactosidase. See Terpe K, et al, Appl. Microbiol. Biotechnol. 2003; 60:523-525.
  • pharmaceutically acceptable carrier refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any conventional type.
  • a pharmaceutically acceptable carrier is essentially non-toxic to recipients at the employed dosages and concentrations and is compatible with other ingredients of the formulation.
  • the carrier for a formulation containing polypeptides would not include normally oxidizing agents and other compounds known to be deleterious to polypeptides.
  • Suitable carriers include, but are not limited to, water, dextrose, glycerol, saline, ethanol, and combinations thereof.
  • the carrier can contain additional agents such as wetting or emulsifying agents, pH buffering agents, or adjuvants that enhance the effectiveness of the formulation.
  • additional agents such as wetting or emulsifying agents, pH buffering agents, or adjuvants that enhance the effectiveness of the formulation.
  • prevent refers to inhibiting the inception or decreasing the occurrence of a disease in an animal. Prevention may be complete (e.g. the total absence of pathological cells in a subject). The prevention may also be partial, such that for example the occurrence of pathological cells in a subject is less than that which would have occurred without the present invention. Prevention also refers to reduced susceptibility to a clinical condition.
  • secretion signal peptide refers to a highly hydrophobic amino acid sequence (e.g. preferably 15 to 60 amino acids long) of proteins that must cross through membranes to arrive at their functioning cellular location. By binding to signal recognition particles, these sequences direct nascent protein-ribosome complexes to a membrane where the protein is inserted during translation. Signal peptides direct translational uptake of the protein by various membranes (e.g. endoplasmic reticulum, mitochondria, chloroplast, peroxisome). Leader signal sequences on non-membrane proteins are ultimately removed by specific peptidases.
  • Some signal peptides used include MCP-3 chemokine, for promoting secretion and attraction of antigen presenting cells; a catenin (CATE)-derived peptide for increased proteasomal degradation; and the lysosomal associated protein, LAMP1 for targeting the MHC II compartment. See Rosati M, et a/., Proc. Natl. Acad. Sci. USA 2009; 106: 15831-15836.
  • sequential administration means that the administration is not simultaneous, but a first administration is performed, followed by one or more successive administrations.
  • the expression “substantially preserves the immunological capabilities of the immunogenic polypeptide”, as used herein, means that the variant shows at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%), at least 90%>, at least 95% or 100% of the ability of the immunogenic polypeptide for inducing an adaptive immune response (i.e. a humoral or cell-mediated immune response), if injected on its own or with adjuvants.
  • an adaptive immune response i.e. a humoral or cell-mediated immune response
  • treat refers to the administration of an immunogenic composition of the invention or of a medicament containing it to control the progression of the disease before or after clinical signs have appeared.
  • Control of the disease progression is understood to mean the beneficial or desired clinical results that include, but are not limited to, reduction of the symptoms, reduction of the duration of the disease, stabilization of pathological states (specifically to avoid additional deterioration), delaying the progression of the disease, improving the pathological state and remission (both partial and total).
  • the control of progression of the disease also involves an extension of survival, compared with the expected survival if treatment was not applied.
  • vacun refers to a substance or composition that establishes or improves immunity to a particular disease by inducing an adaptive immune response including an immunological memory.
  • a vaccine typically contains an agent that resembles a disease-causing microorganism or a part thereof (e.g. a polypeptide). Vaccines can be prophylactic or therapeutic.
  • variant refers to all those amino acid sequences derived from any of SEQ ID NOs 1-16 by means of modifications or mutations, including substitutions, preferably conservative substitutions, insertions or non-terminal deletions, affecting one or more amino acids and which substantially preserves the immunogenic capabilities of the immunogenic polypeptide.
  • vector refers to a nucleic acid molecule, linear or circular, that comprises a segment according to the nucleic acid of interest operably linked to additional segments that provide for its autonomous replication in a host cell of interest or according to the expression cassette of interest.
  • the invention relates to an immunogenic polypeptide having an amino acid sequence comprising the sequences SEQ ID NOs 1-16 or variants of said SEQ ID NO: 1-16, wherein each of said variants has a length of at least 8 amino acids, with the provisos that said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or the variants thereof.
  • the immunogenic polypeptide of the first aspect has an amino acid sequence comprising SEQ ID NO: 49.
  • the invention relates to an immunogenic polypeptide having an amino acid sequence comprising at least one sequence selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof or a fragment thereof, wherein said fragment has a length of at least 8 amino acids, with the provisos that:
  • said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or a variant or a fragment thereof, and
  • the immunogen comprises only one sequence selected from the group consisting of SEQ ID NOs 1-16, then this sequence is not selected from the group consisting of SEQ ID NO: 3, 5, 6 and 16.
  • the variant according to the first and second aspects is equivalent to its related sequence and derives from a different HIV strain or is an artificial HIV sequence. Equivalent in this respect means different in one or more amino acid residues, but corresponding to the same sequence (e.g. determined by the position in the genome or sequence similarity).
  • the variant is a "naturally occurring variant", which refers to nucleic acid sequences derived from an HIV genome of a presently or formerly circulating virus and can be identified from existing databases (e.g. GenBank and Los Alamos sequence databases). The sequence of circulating viruses can also be determined by molecular biology methodologies.
  • a variant of any of SEQ ID NOs 1-16 has an amino acid sequence identity of at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% to its corresponding (i.e. SEQ ID NOs 1-16).
  • BLAST and BLAST 2.0 algorithms See Altschul S, et al, Nuc. Acids Res. 1977; 25:3389-3402 and Altschul S, et al, J. Mol. Biol. 1990; 215:403-410.
  • the BLAST and BLAST 2.0 programs can be used to determine percent sequence identity for the nucleic acids and proteins of the invention.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. See http://blast.ncbi.nlm.nih.gov/blast.cgi, January 2012.
  • Variants may also contain one or more modified amino acid residues (e.g. residues that are modified by the attachment of substituent groups), or one or more unnatural amino acids such as beta amino acids.
  • modified amino acid residues e.g. residues that are modified by the attachment of substituent groups
  • unnatural amino acids such as beta amino acids.
  • Enzyme-linked immunospot non-adherent cells from pre-culture wells are transferred to a plate, which has been coated with the desired anti- cytokine capture antibodies (Abs; e.g. anti-IFN, -IL-10, -IL-2, -IL-4). Revelation is carried out with biotinylated secondary Abs and standard colorimetric or fluorimetric detection methods such as streptavidin-alkaline phosphatase and NBT-BCIP and the spots counted. ELISpot readouts are then expressed as spot- forming cells (SFC)/ 10 6 input cells.
  • SFC spot- forming cells
  • cytokine assay cytokines released in the culture supernatant are measured by different techniques, such as enzyme-linked immunosorbent assays (ELISA), BD cytometric bead array, Biorad Bio-Plex assay and others.
  • ELISA enzyme-linked immunosorbent assays
  • BD cytometric bead array Biorad Bio-Plex assay
  • HLA Class I tetramers Ag-reactive T cells recognizing specific peptide epitopes are detected, using either commercially available reagents (e.g. MHC Class I Dexamers, Immudex, Copenhagen, DK) or in- house generated ones (e.g. Novak E, et ⁇ , J. Clin. Invest. 1999; 104:R63- R67).
  • MHC Class I Dexamers Immudex, Copenhagen, DK
  • Novak E et ⁇ , J. Clin. Invest. 1999; 104:R63- R67.
  • HLA Class II tetramers with this procedure, Ag-reactive T cells recognizing specific peptide epitopes are detected, using either commercially available reagents (e.g. MHC Class II UltimersTM, Prolmmune Ltd, Oxford, GB) or in- house generated ones (e.g. Novak, 1991, supra).
  • commercially available reagents e.g. MHC Class II UltimersTM, Prolmmune Ltd, Oxford, GB
  • in- house generated ones e.g. Novak, 1991, supra.
  • Cytokine capture assays this system is a valid alternative to the ELISpot to visualize Ag-specific T cells according to their cytokine response (Miltenyi Biotec GmbH, Bergisch Gladbach, DE). In addition, it allows the direct sorting and cloning of the T cells of interest.
  • CD 154 assay this procedure is limited to detection of Ag-specific CD4+ T cells. See Chattopadhyay P, et al, Nat. Med. 2005; 11 : 1113-11117 and Frentsch M, et al, Nat. Med. 2005; 11 : 1118-1124.
  • CD 107 assay this procedure allows the visualization of Ag-specific CD8+ T cells with cytotoxic potential. See Betts M, et al, J. Immunol. Methods 2003; 281 :65-78.
  • Methods for determining the extent of the humoral response of a variant are known in the art. Any method suitable for assessing the stimulation of T cells in response to an Ag can be used. Examples of suitable methods include, but are not limited to, detecting or quantitating the relative amount of an antibody, which specifically recognizes an antigenic or immunogenic agent in the sera of a subject who has been treated with an immunogenic polypeptide or variant relative to the amount of the antibody in an untreated subject.
  • Antibody titers can be determined using standard assays such as enzyme-linked immunosorbent assay (ELISA), Single Radial Immunodiffusion Assay (SRID), or Enzyme Immunoassay (ETA).
  • ELISA enzyme-linked immunosorbent assay
  • SRID Single Radial Immunodiffusion Assay
  • ETA Enzyme Immunoassay
  • the variant of any of SEQ ID NOs 1-16 is a fragment of said sequence(s).
  • ancestral viral sequences are determined for the env genes of HIV-1 subtypes B or C, or for the gag genes of subtypes B or C. In other embodiments, the ancestral viral sequence is determined for other HIV genes or polypeptides, such as pol or the auxiliary genes or polypeptides. In yet another embodiment, the viral sequence is determined by consensus or center-of-tree techniques.
  • the HIV is a group M HIV.
  • Group M is the predominant circulating HIV-1 group. It has been divided into subtypes, denoted with letters, and sub-subtypes, denoted with numerals. Subtypes Al, A2, A3, A4, B, C, D, E, Fl , F2, G, H, J, and K are currently recognized. HIV-1 subtypes, also called clades, are phylogenetically linked strains of HIV-1 that are approximately the same genetic distance from one another; in some cases, subtypes are also linked geographically or epidemio logically. Genetic variation within a subtype can be 15 to 20 percent or more, whereas variation between subtypes or divergent members of the same subtype is usually 25 to 35 percent.
  • CRFs and URFs are the result of recombination between subtypes within a dually infected person, from whom the recombinant forms are then passed to other people.
  • the recombinant progeny are classified as circulating recombinant forms if they are identified in three or more people with no direct epidemiologic linkage; otherwise they are described as unique recombinant forms.
  • said immunogen has an amino acid sequence comprising at least one sequence selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, wherein said proviso ii) is: when the immunogen comprises only one sequence selected from the group consisting of SEQ ID NOs 1-16, then this sequence is not selected from the group consisting of SEQ ID NOs 1-16.
  • said immunogen comprises at least two, at least three, or at least four sequences selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, wherein said proviso ii) is: when the immunogen comprises only two, three, or four sequences selected from the group consisting of SEQ ID NOs 1- 16, then not all of these sequences are selected from the group consisting of SEQ ID NO: 3, 5, 6 and 16.
  • said immunogen has an amino acid sequence comprising at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten sequences selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, wherein said proviso ii) is: when the immunogen comprises only two, three, four, five, six, seven, eight, nine or ten sequences selected from the group consisting of SEQ ID NOs 1-16, then not all of these sequences are selected from the group consisting of SEQ ID NOs 1-16.
  • the immunogen according to the first aspect comprises the sequences according to SEQ ID NOs 1-16 or variants thereof in the order
  • the invention relates to the immunogen of the first aspect wherein at least two sequences are adjoined by an amino acid linker.
  • the invention relates to the immunogen of the second aspect, wherein, if said immunogen comprises at least two sequences selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, said sequences are adjoined by an amino acid linker.
  • the linker has the amino acid sequence A, AA or AAA.
  • the linker when the C-terminal residue of the sequence located N-terminally with respect to the linker or the N-terminal residue of the sequence located C-terminally is an alanine residue, the linker can be shortened so that an AAA sequence is formed in the junction region between adjoining sequences.
  • the linker if the C-terminal residue of the sequence located N-terminally with respect to the linker is an alanine or if the N-terminal residue of the sequence located C-terminally with respect to the linker is alanine, the linker has the sequence AA.
  • the linker if the C- terminal residue of the sequence located N-terminally with respect to the linker and the N-terminal residue of the sequence located C-terminally with respect to the linker are both alanine, then the linker as the sequence A.
  • said immunogens further comprise a secretion signal peptide at the N-terminus, wherein said signal peptide preferably enhances secretion of the immunogen from cells expressing said immunogen.
  • a preferred secretion signal peptide is derived from GMCSF (granulocyte macrophage colony- stimulating factor), preferably followed by a valine to increase stability.
  • the sequence of the GMCSF signal peptide is preferably: MWLQSLLLLGTVACSIS (SEQ ID NO: 46) or MWLQSLLLLGTVACSISV (SEQ ID NO: 47).
  • said immunogens further comprise optionally a peptide tag.
  • the peptide tag can be located at the N-terminus between the signal peptide and the immunogenic polypeptide or, preferably, can be located at the C-terminus before the stop codon.
  • said tag is a FLAG peptide.
  • the FLAG system utilizes a short, hydrophilic 8-amino acid peptide, which is fused to the recombinant protein of interest.
  • the FLAG peptide includes the binding site for several highly specific ANTI-FLAG monoclonal antibodies (Ml, M2, M5; Sigma- Aldrich Corp., Saint Louis, MO, US), which can be used to assess expression of the protein of interest on material from transfected cells. Because of the small size of the FLAG peptide tag, it does not shield other epitopes, domains, or alter the function, secretion, or transport of the fusion protein generally.
  • said FLAG peptide has the sequence DYKDDDDKL (SEQ ID NO: 48).
  • said tag is only for expression analysis and purification of the immunogen and it is removed before using it to elicit an immune response.
  • the invention relates to said immunogens, wherein said amino acid sequence comprises at least one antiretroviral resistance mutation site.
  • the mutation can occur at any site within the viral genome.
  • the mutation occurs in the region encoding the integrase, the protease or the reverse transcriptase genes.
  • Mutants within the integrase that confer resistance to integrase inhibitors include, without limitation, T66, E92, F121, E138, G140, Y143, S147, Q148, S153, N155, E157 and R263 within SEQ ID NO: 1 and a combination thereof.
  • the mutation is selected from the group consisting of mutations E92Q, G 140S, G 140A and Y143R in the integrase protein and their combinations.
  • Mutants within the protease associated with protease inhibitor (PI) resistance include major protease, accessory protease, and protease cleavage site mutations. See Shafer R, et ah, AIDS Rev. 2008; 10(2):67-84. Seventeen largely non-polymorphic positions are of the most clinical significance, including L231, L241, D30N, V321, L33F, M461/L, 147/V/A, G48V/M, 150L/V, F53L, 154V/T/A/L/M, G73S/T, L76V, V82A/T/F/S, 184V/A/C, N88D/S, L90M.
  • Accessory protease mutations include the polymorphic mutations L101/V, 113V, K20R/M/I, M36I, D60E, I62V, L63P, A71V/T, V77I, and 193L and the non-polymorphic mutations L10F/R, VI 11, E34Q, E35G, K43T, K45I, K55R, Q58E, A71I/L, T74P/A/S, V751, N83D, P79A/S, 185V, L89V, T91 S, Q92K and C95F.
  • the antiretroviral resistance mutation site is located in the reverse transcriptase, resulting in a resistance to nucleoside reverse transcriptase inhibitor (NRTI) or to non-nucleoside reverse transcriptase inhibitor (NNRTI).
  • NRTI resistance mutations include Ml 84V, thymidine analog mutations (TAMs), mutations selected by regimens lacking thymidine analogs (Non-TAMs), and multi- nucleoside resistance mutations (Multi-NRTI mutations) and many recently described non-polymorphic accessory mutations.
  • Ml 84V non-thymidine-analog- associated mutations such as K65R and L74V, and the multi-nucleoside resistance mutation Q151M act by decreasing NRTI incorporation.
  • Ml 84V is the most commonly occurring NRTI resistance mutation.
  • the most common drug- resistant amino acid mutations are M41L, D67N, K70R, L210W, T215Y/F and K219QE.
  • Non-TAMs non-thymidine analog containing NRTI backbone
  • Non-TAMs Non-thymidine analog containing NRTI backbone
  • Other Non-TAMs mutations include K65N, K70E/G, L741, V75T/M, Y115F.
  • Amino acid insertions at codon 69 generally occur in the presence of multiple TAM, and in this setting are associated with intermediate resistance to 3TC and FTC and high-level resistance to each of the remaining NRTI.
  • Q151 M is a 2-bp mutation (CAG.fwdarw.ATG) that is usually accompanied by two or more of the following mutations: A62V, V751, F77L, and F116Y.
  • the Q151M complex causes high-level resistance to ZDV, d4T, ddl, and ABC, and intermediate resistance to TDF, 3TC, and FTC. See Shafer R, et al., AIDS Rev. 2008; 10(2):67-84
  • NNTRI resistance mutations include, without limitation, the primary NNRTI resistance mutations (K103N/S, V106A/M, Y181C/I/V, Y188L/C/H, and G190A/S/E), the NNRTI resistance secondary mutations (L1001, K101P, P225H, F227L, M230L, and K238T) and rate mutations (V179F, F227C and L2341).
  • Minor non-polymorphic mutations- A98G, K101 E, V 1081, and V 179D/E are common NNRTI resistance mutations that reduce susceptibility to nevirapine and efavirenz about 2-fold to 5-fold.
  • Miscellaneous nonnucleoside reverse transcriptase inhibitor resistance mutations such as K101Q, 1135T/M, V1791, and L2831, reduce susceptibility to nevirapine and efavirenz by about twofold and may act synergistically with primary NNRTI resistance mutations.
  • Other mutations such as L74V, H221Y, K223E/Q, L228H/R, and N3481 are selected primarily by NRTI, yet also cause subtle reductions in NNRTI susceptibility.
  • said antiretroviral resistance mutation site is located in any of SEQ ID NOs 9-11. More preferably, said antiretroviral resistance mutation site is amino acid residue 8 of SEQ ID NO: 9, wherein the amino acid Leu is substituted by the amino acid Met.
  • the variant or fragment has a length of 8 to 40 amino acids, more preferably a length of 11 to 27 amino acids.
  • said variant or fragment does not comprise an amino acid linker adjoining any of SEQ ID NOs 1-16.
  • the C-terminal amino acid of said variant or fragment is neither G, P, E, D, Q, N, T, S, nor C, as these residues do not form a C terminal anchor for HLA class I restricted T cell epitopes generally.
  • said variant or fragment is selected from the group consisting of the peptides according to SEQ ID NOs 17-45.
  • said variant or fragment is combined with or fused to a heat shock protein.
  • the present invention also relates to a fusion protein comprising said variant or fragment and a heat shock protein.
  • Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO.
  • the variant or fragment is a variant or fragment according to the first and second aspects.
  • said variant or fragment does not comprise an amino acid linker adjoining any of SEQ ID NOs 1-16.
  • the C-terminal amino acid of said variant or fragment is neither G, P, E, D, Q, N, T, S, nor C, as these residues do not form a C terminal anchor for HLA class I restricted T cell epitopes generally.
  • said variant or fragment is selected from the group consisting of the peptides according to SEQ ID NOs 17-45.
  • said variant or fragment is combined with or fused to a heat shock protein.
  • the present invention also relates to a fusion protein comprising said variant or fragment and a heat shock protein.
  • Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO.
  • nucleic acids, vectors, viruses and cells of the invention in a third aspect, relates to a nucleic acid encoding for the immunogen of the first aspect, and to an expression cassette, a vector, a virus and a cell comprising said nucleic acid.
  • said nucleic acid is a polynucleotide, referring to single-stranded or double-stranded polymers of nucleotide monomers (nucleic acids), including, but not limited to, 2'-deoxyribonucleotides (DNA) and ribonucleotides (R A) linked by internucleotide phosphodiester bond linkages.
  • the polynucleotides of the invention encode the immunogen of the invention without substantially comprising additional regions of the HIV genome.
  • said nucleic acid is codon optimized.
  • the nucleic acid is codon optimized for expression in humans.
  • Codon- optimized nucleic acids for use according to the present invention can be prepared by replacing the codons of the nucleic acid encoding the immunogen by "humanized" codons (i.e. the codons are those that appear frequently in highly expressed human genes). See Andre S, et ah, J. Virol. 1998; 72: 1497-1503.
  • said codon-optimized nucleic acid has the sequence according to SEQ ID NO: 50.
  • the nucleic acid of the third aspect may require cutting with restriction enzymes in order to it ligate into a vector. This procedure could entail the removal of various terminal nucleotides (e.g. 1, 2, or 3). As such, in one embodiment, the invention relates to said nucleic acid, wherein it has been cut at each end with a restriction enzyme.
  • the present invention relates to an expression cassette comprising the nucleic acid of the third aspect, a promoter sequence and a 3'-UTR and optionally a selection marker.
  • the promoter sequence is a human cytomegalovirus (CMV) promoter or an early-late p7.5 promotor sequence.
  • the 3'-UTR is a bovine growth hormone (BGH) poly- A.
  • the optional selection marker is an antibiotic resistance gene (e.g. kanamycin, ampicilin, tetracycline, spectinomycin) preferably.
  • the present invention relates to an expression vector comprising the nucleic acid or the expression cassette of the third aspect.
  • the vector is an expression vector.
  • suitable vectors according to the present invention include prokaryotic vectors, such as pUC18, pUC19, and Bluescript plasmids and derivatives thereof, like the mpl8, mpl9, pBR322, pMB9, ColEl, pCRl and RP4 plasmids; phages and shuttle vectors, such as pSA3 and pAT28 vectors; expression vectors in yeasts, such as 2-micron plasmid type vectors; integration plasmids; YEP vectors; centromeric plasmids and analogues; expression vectors in insect cells, such as the vectors of the pAC series and of the pVL series; expression vectors in plants, such as vectors of the pIBI, pEarleyGate, pAVA, pCAMBIA, pGSA, pGWB, pMDC, pMY, pORE series and analogues;
  • MVA adenoviruses, viruses associated to adenoviruses, retroviruses and lentiviruses
  • non-viral vectors such as the pSilencer 4.1-CMV (Ambion®, Life Technologies Corp., Carslbad, CA, US), pcDNA3, pcDNA3.1/hyg pHCMV/Zeo, pCR3.1, pEFl/His, pIND/GS, pRc/HCMV2, pSV40/Zeo2, pTRACER-HCMV, pUB6/V5-His, pVAXl, pZeoSV2, pCI, pSVL and pKSV-10, pBPV-1, pML2d and pTDTl vectors.
  • pSilencer 4.1-CMV Ambion®, Life Technologies Corp., Carslbad, CA, US
  • pcDNA3, pcDNA3.1/hyg pHCMV/Zeo
  • the expression vector is a mammalian expression vector comprising a mammalian promoter and a polyadenylation site.
  • the promoter is the human cytomegalovirus (CMV) promoter.
  • the polyadenylation site is the bovine growth hormone (BGH) polyadenylation site.
  • the mammalian expression vector can be modified to optimize vector replication in bacteria.
  • the mammalian expression vector can further comprise a selection gene, for example, a gene coding a protein conferring resistance to an antibiotic.
  • the mammalian expression vector comprises a kanamycin resistance gene
  • the expression vector is a viral vector, preferably a Modified Vaccine Ankara (MVA) virus vector.
  • MVA Modified Vaccine Ankara
  • the present invention relates to a virus containing the nucleic acid of the third aspect.
  • Suitable viruses are safe, have low toxicity and are genetically stable.
  • retroviruses particularly poxviruses such as MVA, lentiviruses, adenoviruses and adeno-associated viruses (AAVs).
  • the present invention relates to a recombinant Modified Vaccinia virus Ankara (MVA) comprising in a polynucleotide or gene construct encoding the immunogenic polypeptides of the invention.
  • Modified Vaccinia Ankara (MVA) virus is related to the vaccinia virus, a member of the genera orthopoxvirus in the family of poxviridae. MVA has been generated by 516 serial passages on chicken embryo fibroblasts of the Ankara strain of vaccinia virus (CVA). See Mayr A, et al, Infection 1975; 3:6-14 and Sutter G, et al, US 6,440,422 and CH 568,392.
  • MVA viruses are publicly available (e.g. ATCC accession number VR-1508). MVA is distinguished by its attenuation (e.g. diminished virulence and limited ability to reproduce infectious virions in certain mammalian cells), while maintaining good immunogenicity and full capacity to replicate and produce infectious virions in avian cells.
  • Suitable MVA strains include strains with enhanced safety due to i) capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF), but no capability of reproductive replication in a human cell line, as in the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarcinoma cell line HeLa; ii) failure to replicate in a mouse model that is incapable of producing mature B and T cells and as such is severely immune compromised and highly susceptible to a replicating virus; and iii) induction of at least the same level of specific immune response in vaccinia virus prime/vaccinia virus boost regimes when compared to DNA-prime/vaccinia virus boost regimes.
  • a suitable attenuated MVA strain in the strain referred to as MVA-BN See Chaplin P, et al, WO2002042480, ECACC accession number V00083008.
  • the present invention relates to a cell comprising the nucleic acid, the expression cassette, the expression vector, or the virus of the third aspect.
  • Cells to be used can be of any cell type, including both eukaryotic cells and prokaryotic cells.
  • the cells include prokaryotic cells, yeast cells, or mammalian cells.
  • Preferred examples of mammalian cells are COS cells, HeLa cells, HEK 293T cells or cells isolated from a patient (e.g. a HIV patient). 4.
  • Compositions of the invention are of the invention.
  • the present invention relates to a composition comprising a variant or fragment according to the first and second aspects and a heat shock protein.
  • Immunogenic compositions can be prepared, for instance, as injectables such as liquid solutions, suspensions, and emulsions.
  • Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO.
  • the invention relates to a pharmaceutical composition comprising an immunogen, nucleic acid, expression cassette, vector or cell according to the invention or a composition according to the fourth aspect and a pharmaceutically acceptable carrier.
  • said pharmaceutical compositions and the composition of the fourth aspect may be used as a vaccine, as laid out below.
  • the present invention relates to a vaccine comprising the immunogen of the first and second aspects, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect or the composition of the fourth aspect.
  • said vaccine is capable of generating cellular and humoral responses. More preferably, the vaccine generates a cytotoxic T cell response.
  • a cytotoxic T cell or cytotoxic T lymphocyte (CTL) assay can be used to monitor the cellular immune response following subgenomic immunization with a viral sequence against homologous and heterologous HIV strains. See Burke S, et ah, J. Inf. Dis. 1994; 170: 1110-1119 and Tigges M, et al, J. Immunol, 1996; 156:3901-3910.
  • T cell responses include, for instance, proliferation assays, lymphokine secretion assays, direct cytotoxicity assays and limiting dilution assays.
  • antigen-presenting cells that have been incubated with a peptide can be assayed for their ability to induce CTL responses in responder cell populations.
  • Antigen-presenting cells can be cells such as peripheral blood mononuclear cells (PBMCs) or dendritic cells (DCs).
  • PBMCs peripheral blood mononuclear cells
  • DCs dendritic cells
  • mutant non-human mammalian cell lines that are deficient in their ability to load MHC class I molecules with internally processed peptides and that have been transfected with the appropriate human MHC class I gene, can be used to test the capacity of a peptide of interest to induce in vitro primary CTL responses.
  • PBMCs can be used as the responder cell source of CTL precursors.
  • the appropriate antigen-presenting cells are incubated with the peptide after which the protein- loaded antigen-presenting cells are incubated with the responder cell population under optimized culture conditions.
  • Positive CTL activation can be determined by assaying the culture for the presence of CTL that kill radiolabeled target cells, both specific peptide-pulsed targets as well as target cells expressing endogenously processed forms of the antigen from which the peptide sequence was derived.
  • the target cells can be radiolabeled with 51 Cr and cytotoxic activity can be calculated from radioactivity released from the target cells.
  • Another suitable method allows the direct quantification of antigen-specific T cells by staining with fluorescein-labeled HLA tetrameric complexes. See Altman J, et al., Proc. Natl. Acad. Sci. USA 1993; 90: 10330-10334 and Altman J, et al, Science 1996; 274:94-96. Other relatively recent technical developments include staining for intracellular lymphokines and interferon release assays or ELISpot assays.
  • the vaccine of the fourth aspect further comprises one or more adjuvants or heat shock proteins.
  • Adjuvants are defines as above.
  • Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO. 6.
  • the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention can be used in the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
  • the invention relates to the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention for use in the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
  • the invention relates to the use of the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention for the manufacture of a medicament for the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
  • the invention in another aspect, relates to a method for the prevention or treatment of an HIV infection or a disease associated with an HIV in a subject in need thereof comprising the administration to said subject of the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention for the manufacture of a medicament for the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
  • the immunogenic peptide, the nucleic acid, the expression cassette the expression vector, the virus, the cell or the vaccine for use according to the invention comprises the sequential administration of :
  • the first the first immunogenic peptide, nucleic acid, expression cassette, expression vector, virus, cell or vaccine are different from the second immunogenic peptide, nucleic acid, expression cassette, expression vector, virus, cell or vaccine.
  • it is first administered an expression vector according to the invention followed by the administration of a Modified Vaccinia Ankara virus according to the invention.
  • the first expression vector according to the invention is administered at least twice, preferably at least three times.
  • the beneficial prophylactic or therapeutic effect of vaccine in relation to HIV infection or AIDS symptoms include, for example, preventing or delaying initial infection of an individual exposed to HIV; reducing viral burden in an individual infected with HIV; prolonging the asymptomatic phase of HIV infection; maintaining low viral loads in HIV infected patients whose virus levels have been lowered via anti- retroviral therapy (ART); increasing levels of CD4 T cells or lessening the decrease in CD4 T cells, both HIV-1 specific and non-specific, in drug naive patients and in patients treated with ART, increasing the breadth, magnitude, avidity and functionality of HIV specific CTL, increasing overall health or quality of life in an individual with AIDS; and prolonging life expectancy of an individual with AIDS.
  • a clinician can compare the effect of immunization with the patient's condition prior to treatment, or with the expected condition of an untreated patient, to determine whether the treatment is effective in inhibiting AIDS.
  • said disease is AIDS, ARC or an HIV opportunistic disease.
  • HIV opportunistic diseases are Burkitt's lymphoma, candidiasis in the bronchi, trachea, lungs, or esophagus, cervical cancer, coccidioidomycosis (disseminated or outside the lungs), cryptococcosis (outside the lungs), cryptosporidiosis (in the intestines lasting for more than 1 month), cytomegalovirus infection (outside the liver, spleen, or lymph nodes), cytomegalovirus retinitis (with loss of vision), HIV encephalopathy, herpes simplex lesions lasting for more than one month, herpes simplex in the bronchi, lung, or esophagus, histoplasmosis (disseminated or outside the lungs), immunoblastic lymphoma, invasive cervical carcinoma (cancer), isosporiasis in the
  • the vaccine of the invention may be useful for the therapy of HIV-1 infection. While all animals that can be afflicted with HIV-1 or their equivalents can be treated in this manner (e.g. chimpanzees, macaques, baboons or humans), the immunogenic compositions of the invention are directed particularly to their therapeutic uses in humans. Often, more than one administration may be required to bring about the desired therapeutic effect; the exact protocol (dosage and frequency) can be established by standard clinical procedures.
  • the present invention further relates to preventing or reducing symptoms associated with HIV infection. These include symptoms associated with the minor symptomatic phase of HIV infection, including, for example, shingles, skin rash and nail infections, mouth sores, recurrent nose and throat infection and weight loss.
  • HIV infection further symptoms associated with the major symptomatic phase of HIV infection include, for instance, oral and vaginal thrush (candidiasis), persistent diarrhea, weight loss, persistent cough and reactivated tuberculosis or recurrent herpes infections, such as cold sores (herpes simplex).
  • Beneficial effects of the invention include, for example, preventing or delaying initial infection of an individual exposed to HIV, reducing viral burden in an individual infected with HIV, prolonging the asymptomatic phase of HIV infection, maintaining low viral loads in HIV infected patients whose virus levels have been lowered via anti- retroviral therapy (ART), increasing levels of CD4 T cells or lessening the decrease in CD4 T cells, both HIV-1 specific and non-specific, in drug na ' ive patients and in patients treated with ART, increasing the breadth, magnitude, avidity and functionality of HIV specific CTL, increasing overall health or quality of life in an individual with AIDS and prolonging life expectancy of an individual with AIDS.
  • a clinician can compare the effect of immunization with the patient's condition prior to treatment, or with the expected condition of an untreated patient, or in a clinical trial of individuals treated and untreated with the vaccine to determine whether the treatment is effective in inhibiting AIDS.
  • the immunogenic compositions can be designed to introduce the nucleic acids or expression vectors to a desired site of action and release it at an appropriate and controllable rate.
  • Methods of preparing controlled-release formulations are known in the art.
  • controlled release preparations can be produced by the use of polymers to complex or absorb the immunogen or immunogenic composition.
  • a controlled-release formulation can be prepared using appropriate macro molecules (e.g. polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) known to provide the desired controlled release characteristics or release profile.
  • Another possible method to control the duration of action by a controlled-release preparation is to incorporate the active ingredients into particles of a polymeric material (e.g. polyesters, polyamino acids, hydrogels, polylactic acid, polyglycolic acid, copolymers of these acids, or ethylene vinylacetate copolymers).
  • a polymeric material e.g. polyesters, polyamino acids, hydrogels, polylactic acid, polyglycolic acid, copolymers of these acids, or ethylene vinylacetate copolymers.
  • Suitable dosages of the nucleic acids and expression vectors of the invention (collectively, the immunogens) in the immunogenic composition of the invention can be readily determined by those of skill in the art.
  • the dosage of the immunogens can vary depending on the route of administration and the size of the subject.
  • Suitable doses can be determined by those of skill in the art, for example by measuring the immune response of a subject, such as a laboratory animal, using conventional immunological techniques, and adjusting the dosages as appropriate.
  • Such techniques for measuring the immune response of the subject include but are not limited to, chromium release assays, tetramer binding assays, IFN ELISPOT assays, IL-2 ELISPOT assays, intracellular cytokine assays, and other immunological detection assays. See Harlow E, Lane D, “Antibodies: A Laboratory Manual” (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, US, 1988).
  • the immunogenic compositions can be administered using any suitable delivery method including, but not limited to, intramuscular, intravenous, intradermal, transcutaneous, intranasal, mucosal (e.g. intrarectal, intravaginal, oral), and topical delivery.
  • suitable delivery method including, but not limited to, intramuscular, intravenous, intradermal, transcutaneous, intranasal, mucosal (e.g. intrarectal, intravaginal, oral), and topical delivery.
  • Such techniques are well known in the art. More specific examples of delivery methods are intramuscular injection, intradermal injection, and subcutaneous injection. However, delivery need not be limited to injection methods.
  • delivery of DNA to animal tissue has been achieved by cationic liposomes direct injection of naked DNA into animal muscle tissue or intradermal injection of DNA using "gene gun” or electroporation technology. See Watanabe M, et al, Mol. Reprod. Dev.
  • the present invention relates to a kit comprising the immunogen of the first aspect, the peptide or variant thereof of the second aspect, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the fourth aspect, or the vaccine of the fourth aspect.
  • kits provide the materials necessary for carrying out the application described in the present invention.
  • the kit could also be in the form of a patch.
  • the kit may comprise a packaging, which allows maintaining the reagents within determined limits. Suitable materials for preparing such packings include glass, plastic (e.g. polyethylene, polypropylene, polycarbonate), bottles, vials, paper, or sachets.
  • the kit of the invention can additionally contain instructions for using the components contained therein, in particularly those constituting the hemostatic patch of the invention. Said instructions can be found in the form of printed material or in the form of an electronic support which can store instructions such that they can be read by a subject, such as electronic storage media (e.g. magnetic disks, tapes), or optical media (e.g. CD-ROM, DVD). The media can additionally or alternatively contain internet websites providing said instructions.
  • GENERAL PROCEDURES e.g. polyethylene, polypropylene, polycarbonate
  • bottles vials, paper, or sachets.
  • the kit of the invention can additionally contain instructions for using the components contained therein, in particularly those constituting the hemostatic patch of the invention. Said instructions can
  • T cell immunogen design The following approach was followed for the design of the HIV OLPs of the invention.
  • PR values in bold indicate PR > 1 , i.e. OLP -responses seen more frequently in individuals with reduced viral loads.
  • the 26 OLPs were aligned and assembled to a total of 16 segments, ranging from 1 1-78 amino acids in length. The precise starting and end positions of these segments were based on analyzing residues in up and down-steam of the identified 26 OLPs and was based on a number of considerations that were applied to the different flanking sites. These considerations included:
  • Sequences SEQ ID NO: 1 to SEQ ID NO: 16 were linked with single, dual or triple alanine amino acids between segments to ensure optimal processing and to avoid premature epitope digestion.
  • the linked segments were used as HIV T cell immunogen sequences for inclusion in DNA and MVA vectors.
  • shorter overlapping peptides (median length 23 residues) were designed that span the 16 segments, not including the triple AAA linkers.
  • These OLPs were generated in a way that helped avoid forbidden residues at the C-terminal end (important for optimal epitope presentation on HLA class I molecules. See SEQ ID NO: 17 to SEQ ID NO: 45, , January 2012).
  • These overlapping peptides range in length from 11-27 amino acids.
  • T cell immunogen The T cell immunogen has been designed as a polypeptide and assembled from
  • T cell 16 segments of the HIV-1 genome of varying size (between 11 to 78 aa) unified by triple alanine linkers. Description of the regions included: T cell
  • Total length 529 (including A, AA or AAA linkers)
  • Signal peptides are generally highly hydrophobic amino acid sequences (15 to 60 amino acids long) of proteins that must cross through membranes to arrive at their functioning cellular location. By binding to signal recognition particles, these sequences direct nascent protein-ribosome complexes to a membrane where the protein is inserted during translation. Signal peptides direct translational uptake of the protein by various membranes (e.g. endoplasmic reticulum, mitochondria, chloroplast, peroxisome). Leader signal sequences on non-membrane proteins are ultimately removed by specific peptidases.
  • Some signal peptides used include MCP-3 chemokine, for promoting secretion and attraction of antigen presenting cells; a catenin (CATE)-derived peptide for increased proteasomal degradation; and the lysosomal associated protein, LAMPl for targeting the MHC II compartment. See Rosati M, et al., Proc. Natl. Acad. Sci. USA 2009; 106: 15831-15836.
  • the signal peptide from GMCSF (granulocyte macrophage colony-stimulating factor) was introduced at the amino -terminus of the immunogen to enhance secretion of the immunogen from expressing cells, followed by a valine to increase stability.
  • the sequence of the GMCSF signal peptide is:
  • the FLAG system utilizes a short, hydrophilic 8 -amino acid peptide, which is fused to the recombinant protein of interest.
  • the FLAG peptide includes the binding site for several highly specific ANTI-FLAG monoclonal antibodies (Ml, M2, M5; Sigma- Aldrich Corp., Saint Louis, MO, US), which can be used to assess expression of the protein of interest on material from transfected cells.
  • the FLAG peptide tag Because of the small size of the FLAG peptide tag, it does not shield other epitopes, domains, or alter the function, secretion, or transport of the fusion protein generally. This sequence was removed afterwards for the mice immunogenicity assay. The FLAG tag is removed from the final immunogen (298H) before immunization.
  • T cell immunogen has the following sequence (SEQ ID NO: 49):
  • the T cell immunogen sequence was translated into a RNA/codon-optimized nucleotide sequence to enhance expression and secretion (Mr. Gene GmbH, Regensburg, DE). Codon optimization was based on introducing multiple nucleotide changes to destroy the previously identified RNA processing, inhibitory and instability sequences in the mRNA without affecting the encoded protein. See Schwartz S, et ah, J. Virol. 1992; 66(12): 7176-7182. This process can also include the elimination of predicted splice sites (score>0.4) from coding sequences by appropriate codon changes, to minimize the possibility of splicing.
  • the codon-optimized T cell immunogen was cloned into the mammalian expression plasmid BV5, which consists of a modified CMV basic plasmid backbone optimized for growth in bacteria that harbors the human cytomegalovirus (CMV) promoter, the bovine growth hormone (BGH) polyadenylation site and the kanamycin resistance gene— lacking the Xho site.
  • CMV human cytomegalovirus
  • BGH bovine growth hormone
  • an amino acid change from Leu to Meth was introduced into the synthesized T cell immunogen -one including the FLAG epitope at RT 41 position (segment 9) to cover one of the major antiretroviral resistance mutations site.
  • the T cell immunogen gene (starting vector) was cloned in a spectomycin resistance harboring plasmid.
  • a PCR-generated segment covering the RT M41 change was inserted into the T cell immunogen as Spel/Hindlll. Competent cells DH108B were used for transformation and were grown on LB-spectomycin media.
  • the resulting plasmid was named HIV AC AT RT M41. Insertion of the point mutation was confirmed by PCR sequencing using sense and antisense primers covering the segment 9 sequence.
  • the HIV AC AT RT M41 gene was inserted to the BV5 plasmid that lacks the Xho site in kanamycin resistance gene as Sall/EcoRI, by ligation of the vector and the gel purified digested HIV AC AT RT M41 fragment. Competent cells DH108B were used for transformation and were grown in LB-Kan media. Resulting plasmid name was 297H (GMCSF- HIVACAT-FLAG). Insertion of the gene was confirmed by restriction digestion and PCR sequencing using sense (from the CMV promoter) and antisense primers (from the polyA BGH region).
  • the epitope for the FLAG tag was removed from the 297H plasmid by BstEII-EcoRI digestion and insertion the annealed primers 298H Plus and 298H Minus:
  • the resulting plasmid was named 298H GMCSF-HIVACAT, accession number DSM 25555). See Fig 1. Removal of the FLAG tag was confirmed by PCR sequencing using antisense primers (from the polyA BGH region).
  • HEK 293 cells were transfected by CaPhosphate DNA co -precipitation with a total of 7 ⁇ g of DNA (lOOng or 250ng of the 297H GMCSF-HIVACAT-FLAG plasmid DNA, 50 ng of GFP expressing plasmid pFRED143 topped up to 7 ⁇ g with Bluescript DNA).
  • Protein expression was analyzed by Western immunoblots. 1/250 of the total of the cell extracts and supernatants were loaded. The proteins were resolved by electrophoresis on 10% sodium dodecyl sulfate polyacrylamide gels (Nu-Page Bis-Tris, NuPAGE, Invitrogen, Life Technologies Corp., Carlsbad, CA, US) and transferred onto nitrocellulose membranes.
  • Positive controls were used and included plasmid DNA encoding for clade B p55 Gag, which also harbored the FLAG tag.
  • a stock of 1ml (2mg/ml) of 298H GMCSF-HIVACAT DNA was produced endofree for in vivo studies in mice.
  • BV4 CMV-kan-Basic SHAM control, similar DNA plasmid backbone without any expressed transgene.
  • mice 35 mice were used in the experiment, pooling 5 mice per group. Distribution of the immunization per group was as follows:
  • mice pooled isolated mouse splenocytes from each group of mice were incubated at a density if 2xl0 6 cells/ml, in 1 ml co-culture overnight, in the presence of peptide pools (15-mers, overlapping by 1 laa covering clade B gag, consensus B pol and NL43 nef, tat and vif sequences, 1 ⁇ g/ml each peptide, total of about 12 hours, 1 hour without Golgi stop to prevent cytokine secretion).
  • Surface immunostaining was performed with CD3- allophycocyanin-Cy7, CD4-PerCP, CD8-Pacific Blue (BD Biosciences, Inc., Franklin Lakes, NJ, US). Intracellular cytokine staining was performed using interferon gamma-FITC antibody (BD Biosciences, Inc., Franklin Lakes, NJ, US) after permeabilization.
  • mice At an individual mice level, responses were deconvo luted using frozen splenocytes stimulated with 8 pools of peptides to cover the protein subunits included in the immunogen in an interferon gamma ELISpot assay.
  • ELISpot assay was performed by using mouse interferon gamma ELISpot kit (ALP) (Mabtech AB, Sweden, SE) following the manufacturer's instructions with minor modifications. For all assays, mice splenocytes were added at an input cell number of 4xl0 5 cells/well in 140 ⁇ 1 of Rosewell Park Memorial Institute medium 1640 with 10% fetal bovine serum in 96-well polyvinylidene plates (Millipore Corp., Bedford, MA, US) alone or with HIV-1- specific peptide pools (14 ⁇ g/ml final concentration for each peptide) for 16hours at 37°C in 5% C0 2 .
  • ALP mouse interferon gamma ELISpot kit
  • HIV peptides pools used in mice immunized with DNAs expressing full gag, pol, nef, tat and vif proteins consisted of 18-mers peptides with an overlap of 11 residues spanning the complete gag (6 pools, 11 peptides/each), pol (8 pools, 16 or 17 peptides/each), nef (2 pools, 13 o 14 peptides/each), tat (1 pool, 12 peptides) and vif (2 pools, 12 peptides/each) proteins.
  • Concavalin A (Sigma-Aldrich Corp., Saint Louis, MO, US), at 5 mg/ml, was used as a positive control.
  • the plates were developed with one-step 5-bromo-4-chloro- 3-indolyl phosphate/Nitroblue Tetrazolium (BCIP/NBT, Bio-Rad Laboratories, Inc., Irvine, CA, US).
  • the spots on the plates were counted using an automated ELISPOT reader system (CTL Analyzers LLC, Cleveland, OH, US) using ImmunoSpot software and the magnitude of responses was expressed as spot forming cells (SFC) per million input splenocytes.
  • the threshold for positive responses was defined as at least 5 spots per well and responses exceeding the "mean number of spots in negative control wells plus 3 standard deviations of the negative control wells" and "three times the mean of negative control wells", whichever was higher.
  • HIVACAT T cell immunogen sequence Median breadth of responses to protein subunits included in the HIVACAT T cell immunogen sequence was 4 (range 2-5) in mice immunized with 20 ⁇ g of HIVACAT vs 2 responses (range 1-3) in mice immunized with 20 ⁇ g of plasmids encoding for entire proteins (ns) with no significant differences in the magnitude of responses. Six out of the eight protein subunits were at least targeted once in the mice immunized with the HIVACAT T cell immunogen. See Fig.4. HIVACAT Mice making a
  • HIV-1 protein response groups immunogen number pool (groups Gag- HIVACAT) segments Pol-NTV)
  • Humoral responses were first analyzed in pooled mice sera. Binding antibodies to p24, p37 and p55 were detected by western immunoblot by using cell extracts from HEK 293cells transfected with the lmg of gag expression vectors separated on 12% SDS-Page and probing the membranes with pooled sera from mice (at a 1 : 100 dilution). Antibody titers to gag p24 were measured by ELISA. Serial 4-fold dilutions of the pooled serum samples were assessed and the optical absorbance at 450nm was determined (Advanced Bioscience Lab, Inc., Kensington, MD, US). The binding titers were reported as the highest dilution scoring positive having a value higher than the average plus 3 standard deviations obtained with control sera from the mice immunized with SHAM DNA.
  • HIVACAT T cell immunogen induced binding antibody responses to gag p55, p37 and p24 detectable by Western blot in the group of mice immunized with 20 ⁇ g. See Fig 6.
  • mice sera at 1 : 100 dilution. Low levels of antibody were detectable in 2 out of 3 mice immunized with the high dose of the immunogen. See Fig 7b.
  • the codon-optimized T cell immunogen was cloned into the mammalian expression plasmid BV5, which consists of a modified CMV basic plasmid backbone optimized for growth in bacteria that harbors the human cytomegalovirus (CMV) promoter, the bovine growth hormone (BGH) polyadenylation site and the kanamycin resistance gene— lacking the Xho site.
  • CMV human cytomegalovirus
  • BGH bovine growth hormone
  • the plasmid DNA for mice immunizations was prepared using the Endo-Free Megaprep (Qiagen) and stored -80°C until use.
  • a recombinant MVA expressing the HIVACAT gene was made as described previously ⁇ Letourneau, 2007 #235; Nkolola, 2004 #321 ⁇ .
  • chicken embryo fibroblast (CEF) cells grown in Dulbeco's Modified Eagle's Medium supplemented with 10% FBS, penicillin/streptomycin and glutamine (DMEM 10) were infected with parental MVA at MOI 1 and transfected using Superfectin (Quiagen) with 3ug of pDNA-HIVACAT carrying the ⁇ -galactosidase gene as a marker. Two days later, the total virus was harvested and used to re-infect CEF cells. MVA was subjected to five round of plaque purification, after which a master virus stock was grown, purified on a 36%o sucrose cushion, tittered and stored at -80°C until use.
  • mice For heterologous prime/boost in-vivo immunogenicity experiments in mice, groups of five 6-to 8-weeks-old female C57BL/6 (Harlan Laboratories Ltd., Barcelona, Spain) were used. Mice were primed intramuscularly with 100 ⁇ g of pDNA-HIVACAT (2 or 3 vaccinations) followed by a 10 A 6 pfu of MVA-HIVACAT boost (groups: 2xDNA, 3xDNA, 2xDNA + 1 MVA and 3xDNA + 1 MVA respectively) All vaccinations were separated by three weeks.
  • mice All mice were sacrificed two weeks after the last vaccination in each experiment. Mice splenocytes and serum were harvested for immunogenicity studies. Spleens were removed and pressed individually through a cell strainer (Falcon) using a 5 -ml syringe rubber punger. Following rbc lysis, splenocytes were washed and resuspended in RPMI 1640 supplemented with 10%> FCS, penicillin/streptomycin (R10) and frozen until use.
  • Falcon cell strainer
  • splenocytes were washed and resuspended in RPMI 1640 supplemented with 10%> FCS, penicillin/streptomycin (R10) and frozen until use.
  • ELISpot assay was performed by using mouse IFNy ELISpot kit (ALP)
  • mice splenocytes were first thawed and rested for 5h 37°C in RIO before use. Cells were added at an input cell number of 4xl0 5 cells/well in 140 ⁇ 1 of RIO in 96-well polyvinylidene plates (Millipore Corp., Bedford, MA, US) alone or with HIV-1- specific peptide pools (14 ⁇ g/ml final concentration for each peptide) for 16hours at 37°C in 5% C0 2 . Concavalin A (Sigma-Aldrich Corp., Saint Louis, MO, US), at 5 mg/ml, was used as a positive control.
  • the plates were developed with one-step 5-bromo-4-chloro-3-indolyl phosphate/Nitroblue Tetrazolium (BCIP/NBT, Bio-Rad Laboratories, Inc., Irvine, CA, US).
  • the spots on the plates were counted using an automated ELISPOT reader system (CTL Analyzers LLC, Cleveland, OH, US) using ImmunoSpot software and the magnitude of responses was expressed as spot forming cells (SFC) per million input splenocytes.
  • SFC spot forming cells
  • the threshold for positive responses was defined as at least 5 spots per well and responses exceeding the "mean number of spots in negative control wells plus 3 standard deviations of the negative control wells" and "three times the mean of negative control wells", whichever was higher.
  • MVA-HIVACAT vaccine was able to boost responses both in breadth and magnitude, (Fig 8B) in the two groups analyzed, but did just significantly increase the magnitude of responses when mice had previously been primed with three doses of pDNA-HIVACAT (Fig 8B and 8C).
  • Fig 8B and 8C a balanced and broad response to most of all the protein- subunits included in the immunogen was observed in all animals, without a clear pattern of dominance among them. No nef or gag-pl5 specific responses were detected in the studied mice (Fig 8D).

Abstract

The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Description

IMMUNOGENS FOR HIV VACCINATION
FIELD OF THE INVENTION The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom. It also relates to isolated nucleic acids expressing these immunogens as well as vectors and cells comprising such nucleic acids. The compounds of the present invention are useful as vaccines, particularly for the prevention and treatment of AIDS and opportunistic diseases.
BACKGROUND OF THE INVENTION
HIV infection induces strong and broadly directed, HLA class I restricted T cell responses for which specific epitopes and restricting HLA alleles have been implicated in the relative in vivo control. See Brander C, et al, Current Opinion Immunol. 2006; 18: 1-8. While the bulk of the anti-viral CTL response appears to be HLA-B restricted, the relative contribution of targeted viral regions and restricting HLA molecules on the effectiveness of these responses remains obscure. See Kiepiela P, et al, Nature 2004; 432:769-775 and Ngumbela K, et al, AIDS Res. Hum. Retroviruses 2008; 24:72-82.
In addition, the role that HIV sequence diversity plays in the in vivo relevance of virus-specific T cell immunity is unclear, as functional constraints of escape variants, codon-usage at individual protein positions, T cell receptor (TCR) plasticity and functional avidity and cross-reactivity potential may all contribute to the overall effectiveness of a specific T cell response. See Brockman M, et al, J. Virol. 2007; 81 : 12608-12618 and Yerly D, et al, J. Virol. 2008; 82:3147-3153. Of note, T cell responses to HIV Gag have most consistently been associated with reduced viral loads in both, HIV clade B and clade C infected cohorts. See Zuniga R, et al, J. Virol. 2006; 80:3122-3125 and Kiepiela P, et al, Nat. Med. 2007; 13:46-53.
However, none of these analyses assessed the role of responses to shorter regions of the targeted protein(s) that may induce particularly effective responses. In addition, it is unclear whether the relative benefit of Gag is due to any other specific characteristic of this protein, such as expression levels, amino acid composition and inherently greater immunogenicity. It is thus feasible that protein subunits outside of Gag and within these, specific short epitope-rich regions could be identified that: i) induce responses predominantly seen in HIV controllers and ii) which would be detectable in individuals of diverse HLA types, not limited to individuals expressing alleles previously associated with effective viral control.
While some of the earlier studies have indeed controlled for a potential over- representation of Gag-derived epitopes presented on "good" HLA class I alleles, concerns remain that a purely Gag-based HIV vaccine might mainly benefit those people with an advantageous HLA genotype and will not take advantage of potentially beneficial targets outside of Gag. See Kiepiela, 2007, supra and Honeyborne I, et al, J. Virol. 2007; 81 :3667-3672. In addition, CTL escape and viral fitness studies have largely been limited to Gag-derived epitopes presented in the context of relatively protective HLA alleles such as HLA-B57 and -B27. See Schneidewind A, et al, J. Virol. 2007; 81 : 12382-12393 and Leslie A, et al, Nat. Med. 2004; 10:282-289. The available information may thus not provide relevant information for immunogen sequences designed to protect the genetically diverse majority of the human host population.
Furthermore, many studies have focused on immunodominant targets only, despite some recent studies in HIV and SIV infection demonstrating a crucial contribution of sub-dominant responses in in vivo viral control, among them targets located outside of Gag. See Frahm N, et al, Nat. Immunol. 2006; 7: 173-178 and Friedrich T, et al, J. Virol. 2007; 81 :3465-3476. Together, the current view on what may constitute a protective cellular immune response to HIV is thus quite likely biased towards a focus on immunodominant responses and on responses restricted by frequent HLA class I alleles and HLA alleles associated with superior disease outcome. Therefore, the development of HIV vaccines is limited in part by the lack of immunogens capable of inducing a broad immune response. The present invention addresses the design of such immunogens. SUMMARY OF THE INVENTION In a first aspect, the invention relates to an immunogenic polypeptide having an amino acid sequence comprising the sequences SEQ ID NOs 1-16 or variants of said SEQ ID NO: 1-16, wherein each of said variants has a length of at least 8 amino acids, with the provisos that said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or the variants thereof.
In a second aspect, the invention relates to an immunogenic polypeptide having an amino acid sequence comprising at least one sequence selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof wherein said variant has a length of at least 8 amino acids, with the provisos that:
i) said immunogen amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or a variant or a fragment thereof, and
ii) when the immunogen comprises only one sequence selected from the group consisting of SEQ ID NOs 1-16, then this sequence is not selected from the group consisting of SEQ ID NO: 3, 5, 6 and 16.
In further aspects, the invention relates to nucleic acids encoding for the immunogens of the first aspect and second aspects, and to expression cassettes, vectors, a viruses and cells comprising said nucleic acids.
In another aspect, the present invention relates to a vaccine comprising an immunogenic polypeptide according to any of claims 1 to 11 and one or more adjuvants.
In another aspect, the present invention relates to the immunogenic polypeptide, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect, or the composition vaccine for use in medicine.
In another aspect, the present invention relates to the immunogenic polypeptide, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect, or the composition vaccine for use in the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
In another aspect, the present invention relates to a kit comprising the immunogen of the first and/or second aspects, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect, or the composition of the fourth aspect.
DEPOSIT OF MICROORGANISMS
The plasmid 298H GMC SF-HI VAC AT DNA was deposited on January 13th, 2012, under accession number DSM 25555 at the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen, InhoffenstraBe 7 B, D-38124 Braunschweig, Federal Republic of Germany.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. Schematic representation of the gene included in the expression plasmid. Dots identify start and stop codons.
Figure 2. Cellular immune responses analyzed in pooled splenocytes by flow cytometric analysis. Frequency of total Gag, Pol, and Nef-Tat-Vif specific interferon gamma responses among groups in (a) and distribution of CD4 and CD8 responses in (b) are shown.
Figure 3. Responses to Gag, Pol, NTV and the HIVACAT T cell immunogen sequence measured by interferon gamma ELISpot assay in murine splenocytes. The individual mice were immunized with the plasmids encoding for the full Gag, Pol and Nef-Tat-Vif polypeptide. Contribution of the responses targeting the regions included in the HIVACAT T cell immunogen to the total interferon gamma Gag-Pol-NTV specific response is shown.
Figure 4. Comparison of the breadth in (a) and magnitude in (b) of the interferon gamma responses targeting the HIVACAT T cell immunogen in immunized mice. The subjects were treated with either the plasmids encoding the full proteins or the minimal T cell sequence.
Figure 5. Balance of interferon gamma responses against Gag, Pol, Vif or Nef for mice immunized with 20 μg of plasmids encoding full Gag, Pol plus Nef-Tat-Vif polypeptide and HIVACAT T cell immunogen. Dominance of Gag-specific responses in shown in panel (a) for mice immunized with full proteins whereas a more balance repertoire in seen in panel (b) for mice immunized with the HIVACAT T cell immunogen.
Figure 6. Binding antibodies to p24, p37 and p55 detected by Western immunoblot by using cell extracts from HEK 293 cells transfected with the lmg of gag and gag-pol expression vectors (showing p55 gag, and processed p24, p37 and p55 gag subunits) separated on 12% SDS-Page and probing the membranes with a) human sera of and HIV-infected patient, b) pooled sera from mice immunized with high doses of the immunogen and c) pooled sera from mice immunized with low doses of the immunogen (all at a 1 : 100 dilution).
Figure 7. a) Endpoint titers of Gag-p24 specific binding antibody from treated mice. The determination was performed by ELISA from individual serial 4-fold diluted pooled serum samples, b) In house developed gag p55 ELISA using the HIV-1IIIB pr55 Gag recombinant protein (Cat. No. 3276, NIH Reagent Program, Bethesda, MD, US). The determination was performed in individual mice sera at 1 : 100 dilution.
Figure 8. a) Schematic representation of mice immunizations. Groups of six
C57BL/6 mice were used to compare immunogenicity of the different heterologous combinations (2xDNA prime vs 3xDNA prime followed by IxMVA boost) using either 100μg of pDNA-HIVACAT or 10Λ6 pfu of MVA-HIVACAT by intramuscular injection, b) Comparison of the breadth and magnitude of the ΙΚΝγ responses targeting HIVACAT T cell immunogen in individual immunized mice, c) Distribution of Gag, Pol,Vif and Nef specific responses in individual immunized mice, d) Distribution among the 8 protein subunits included in the HIVACAT T cell immunogen (Gag pi 7, Gag p24, Gag p2p7plp6, Pol-Protease, Pol-RT, Pol-Integrase, Vif and Nef) in different immunization groups is shown.
DETAILED DESCRIPTION OF THE INVENTION
The invention discloses several immunogenic compounds effective for inducing a high immune response against HIV in a broad range of subjects. In particular, HIV- specific CD4+ and CD8+ T cell responses to key HIV-encoded epitopes have been obtained with these compounds. 1. Definitions of general terms and expressions
The term "adjuvant", as used herein, refers to an immunological agent that modifies the effect of an immunogen, while having few if any direct effects when administered by itself. It is often included in vaccines to enhance the recipient's immune response to a supplied antigen, while keeping the injected foreign material to a minimum. Adjuvants are added to vaccines to stimulate the immune system's response to the target antigen, but do not in themselves confer immunity. Non-limiting examples of useful adjuvants include mineral salts, polynucleotides, polyarginines, ISCOMs, saponins, monophosphoryl lipid A, imiquimod, CCR-5 inhibitors, toxins, polyphosphazenes, cytokines, immunoregulatory proteins, immunostimulatory fusion proteins, co-stimulatory molecules, and combinations thereof. Mineral salts include, but are not limited to, AIK(S04)2. AlNa(S04)2, A1NH(S04)2, silica, alum, Al(OH)3, Ca3(P04)2, kaolin, or carbon. Useful immunostimulatory polynucleotides include, but are not limited to, CpG oligonucleotides with or without immune stimulating complexes (ISCOMs), CpG oligonucleotides with or without polyarginine, poly IC or poly AU acids. Toxins include cholera toxin. Saponins include, but are not limited to, QS21, QS17 or QS7. An example of a useful immunostimulatory fusion protein is the fusion protein of IL-2 with the Fc fragment of immunoglobulin. Useful immunoregulatory molecules include, but are not limited to, CD40L and CD la ligand. Cytokines useful as adjuvants include, but are not limited to, IL-1, IL-2, IL-4, GMCSF, IL-12, IL-15, IGF-1, IFN-a, IFN-β, and interferon gamma. Also, examples of are muramyl dipeptides, N- acetyl-muramyl-L-threonyl-D-isoglutamine (thr-DMP), N-acetyl-nornuramyl-L-alanyl- D-isoglutamine (CGP 11687, also referred to as nor-MDP), N-acetylmuramyul-L- alanyl-D-isoglutaminyl-L-alanine-2-(l '2'-dipalmitoyl-sn-glycero-3- hydroxphosphoryloxy)-ethylamine (CGP 19835 A, also referred to as MTP- PE), RIBI (MPL+TDM+CWS) in a 2 percent squalene/TWEEN® 80 emulsion, lipopolysaccharides and its various derivatives, including lipid A, Freund's Complete Adjuvant (FCA), Freund's Incomplete Adjuvants, Merck Adjuvant 65, polynucleotides (e.g. poly IC and poly AU acids), wax D from Mycobacterium tuberculosis, substances found in Corynebacterium parvum, Bordetella pertussis, and members of the genus Brucella, Titermax, Quil A, ALUN, Lipid A derivatives, choleratoxin derivatives, HSP derivatives, LPS derivatives, synthetic peptide matrixes or GMDP, Montanide ISA-51 and QS-21, CpG oligonucleotide, poly I:C, and GMCSF. See Osol A., Ed., Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA, US, 1980, pp. 1324-1341), Hunter R, US 5,554,372, and Jager E, Knuth A, WO1997028816. Combinations of adjuvants can also be used.
The term "AIDS", as used herein, refers to the symptomatic phase of HIV infection, and includes both Acquired Immune Deficiency Syndrome (commonly known as AIDS) and "ARC," or AIDS-Related Complex. See Adler M, et al, Brit. Med. J. 1987; 294: 1145-1147. The immunological and clinical manifestations of AIDS are well known in the art and include, for example, opportunistic infections and cancers resulting from immune deficiency.
The term "amino acid linker", as used herein, refers to an amino acid sequence other than that appearing at a particular position in the natural protein and is generally designed to be flexible or to interpose a structure, such as an a-helix, between two protein moieties. A linker is also referred to as a spacer. The linker is typically non- antigenic and can be of essentially any length (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acids). The linker may also be a location or sequence where the cellular antigen processing machinery can initiate the degradation of the immunogenic polypeptide without destroying potent T cell epitopes).
The term "antiretroviral resistance mutation site", as used herein, relates to a site that, when mutated, confers resistance to an antiretroviral agent. Such sites can be identified by mining known databases such as the Stanford University HIV Drug Resistance Database, where, for example, sequences and treatments from viruses with specific mutations or drug susceptibility data for isolates with selected mutations can be retrieved. Assays for testing drug resistance of HIV are known in the art. See Dong J, US 20040106136 and Shafer R, Assay for Antiretroviral Resistance, HIV InSite Knowledge Base Chapter (http://hivinsite.ucsf.edu/InSite?page=kb-02-02-03, January 2012). Already known antiretroviral resistance mutation sites in HIV are regularly published by the World Health Organization or the by the International Antiviral Society-USA (e.g. Johnson V, et al, ISA-USA Topics Antiviral Med. 2011; 19(4): 153- 164. The expression "cellular immune response", as used herein, describes an immune response against foreign antigen(s) that is mediated by T cells and their secretion products.
The term "center-of-tree sequence" or "COT", as used herein, refers to a sequence from which the average evolutionary distance to each tip of a phylogenetic diagram of related variant sequences has been minimized. See Nickle D, et al, Science 2003; 299, 1515-1517.
The term "codon optimized", as used herein, relates to the alteration of codons in nucleic acid molecules to reflect the typical codon usage of the host organism without altering the polypeptide encoded by the DNA, to improve expression. A plethora of methods and software tools for codon optimization have been reported previously. See Narum D, et al, Infect. Immun. 2001; 69(12):7250-7253, Outchkourov N, et al, Protein Expr. Purif. 2002; 24(l): 18-24, Feng L, et al, Biochemistry 2000; 39(50): 15399-15409, and Humphreys D, et al, Protein Expr. Purif. 2000; 20(2):252-2.
The term "comprising" or "comprises", as used herein, discloses also "consisting of according to the generally accepted patent practice.
The expression "disease associated with a HIV infection", as used herein, includes a state in which the subject has developed AIDS, but also includes a state in which the subject infected with HIV has not shown any sign or symptom of the disease. Thus, the vaccine of the invention when administered to a subject that has no clinical signs of the infection can have a preventive activity, since they can prevent the onset of the disease. The immunogenic compositions are capable of preventing or slowing the infection and destruction of healthy CD4+ T cells in such a subject. It also refers to the prevention and slowing the onset of symptoms of the acquired immunodeficiency disease such as extreme low CD4+ T cell count and repeated infections by opportunistic pathogens such as Mycobacteria spp., Pneumocystis carinii, and Pneumocystis cryptococcus . Beneficial or desired clinical results include, but are not limited to, an increase in absolute naive CD4+ T cell count (range 10-3520), an increase in the percentage of CD4+ T cell over total circulating immune cells (range 1-50 percent), and/or an increase in CD4+ T cell count as a percentage of normal CD4+ T cell count in an uninfected subject (range 1-161 percent).
The terms "variant" or "fragment", as used herein, refer to a polypeptide derived from any of SEQ ID NOs 1-16 by deletion of one or more terminal amino acids at the N-terminus or at the C-terminus of an individual SEQ ID NO. Variant or fragments preferably have a length of at least 8 amino acids or up to 10%, up to 20%>, up to 30%>, up to 40%, up to 50%, up to 60%, up to 70%, up to 80%, up to 90%, or up to 99% of its respective SEQ ID NO.
The term "HIV genome", as used herein, refers to a RNA sequence approximately 8749 nucleotide long enclosed by the HIV capsid and encoding the genes gag, pol, env, tat, rev, vif, nef, vpr, vpu, vpx, and optionally, tev. The HIV genome sequence underlies high variability, for this reason, the HIV genome referred to in the invention is not limited to any specific sequence. Preferred sequences are those of the HIV types and subtypes recited herein.
The term "human immunodeficiency virus" or "HIV", as used herein, refer human immunodeficiency viruses generically and includes HIV type 1 ("HIV-l"), HIV type 2 ("HIV-2") or other HIV viruses, including, for example, the HIV-l, HIV-2, emerging HIV and other HIV subtypes and HIV variants, such as widely dispersed or geographically isolated variants and simian immunodeficiency virus ("SIV"). For example, an ancestral viral gene sequence can be determined for the env and gag genes of HIV-l, such as for HIV-l subtypes A, B, C, D, E, F, G, H, J, and K, and intersubtype recombinants such as AG, AGI, and for groups M, N, O or for HIV-2 viruses or HIV-2 subtypes A or B. HIV-l, HIV-2 and SIV include, but are not limited to, extracellular virus particles and the forms of the viruses associated with their respective infected cells.
The "humoral immune response", as used herein, describes an immune response against foreign antigen(s) that is mediated by antibodies produced by B cells.
The term "immunogenic composition", as used herein, refers to a composition that elicits an immune response that produces antibodies or cell-mediated immune responses against a specific immunogen.
The term "immunogenic polypeptide" or "immunogen", as used herein, refers to a polypeptide antigen that is able to induce an adaptive immune response (i.e. a humoral or cell-mediated immune response), if injected on its own or with an adjuvant. The term "kit", as used herein, refers to a combination of articles that facilitate a process, method or application. These kits provide the materials necessary for carrying out the application described in the present invention.
The term "operably linked", as used herein, is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). See Auer H, Nature Biotechnol. 2006; 24: 41-43.
The term "peptide tag" or "tag", as use herein, refers to a peptide or amino acid sequence, which can be used in the isolation or purification of said immunogen. Thus, said tag is capable of binding to one or more ligands, for example, one or more ligands of an affinity matrix such as a chromatography support or bead with high affinity. Illustrative, non-limitative, examples of tags useful for isolating or purifying a protein include Arg-tag, FLAG-tag, His-tag, or Strep-tag; an epitope capable of being recognized by an antibody, such as c-myc-tag (recognized by an anti-c-myc antibody), SBP-tag, S-tag, calmodulin binding peptide, cellulose binding domain, chitin binding domain, glutathione S-transferase-tag, maltose binding protein, NusA, TrxA, DsbA or Avi-tag; an amino acid sequence, such as AHGHRP (SEQ ID NO:53), PIHDHDHPHLVIHS (SEQ ID NO:54), or GMTCXXC (SEQ ID NO:55); or β- galactosidase. See Terpe K, et al, Appl. Microbiol. Biotechnol. 2003; 60:523-525.
The terms "pharmaceutically acceptable carrier," "pharmaceutically acceptable diluent," or "pharmaceutically acceptable excipient", or "pharmaceutically acceptable vehicle," as used interchangeably herein, refer to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any conventional type. A pharmaceutically acceptable carrier is essentially non-toxic to recipients at the employed dosages and concentrations and is compatible with other ingredients of the formulation. For example, the carrier for a formulation containing polypeptides would not include normally oxidizing agents and other compounds known to be deleterious to polypeptides. Suitable carriers include, but are not limited to, water, dextrose, glycerol, saline, ethanol, and combinations thereof. The carrier can contain additional agents such as wetting or emulsifying agents, pH buffering agents, or adjuvants that enhance the effectiveness of the formulation. The terms "prevent," "preventing," and "prevention", as used herein, refer to inhibiting the inception or decreasing the occurrence of a disease in an animal. Prevention may be complete (e.g. the total absence of pathological cells in a subject). The prevention may also be partial, such that for example the occurrence of pathological cells in a subject is less than that which would have occurred without the present invention. Prevention also refers to reduced susceptibility to a clinical condition.
The term "secretion signal peptide" refers to a highly hydrophobic amino acid sequence (e.g. preferably 15 to 60 amino acids long) of proteins that must cross through membranes to arrive at their functioning cellular location. By binding to signal recognition particles, these sequences direct nascent protein-ribosome complexes to a membrane where the protein is inserted during translation. Signal peptides direct translational uptake of the protein by various membranes (e.g. endoplasmic reticulum, mitochondria, chloroplast, peroxisome). Leader signal sequences on non-membrane proteins are ultimately removed by specific peptidases. Some signal peptides used include MCP-3 chemokine, for promoting secretion and attraction of antigen presenting cells; a catenin (CATE)-derived peptide for increased proteasomal degradation; and the lysosomal associated protein, LAMP1 for targeting the MHC II compartment. See Rosati M, et a/., Proc. Natl. Acad. Sci. USA 2009; 106: 15831-15836.
The expression "sequential administration", as used herein, means that the administration is not simultaneous, but a first administration is performed, followed by one or more successive administrations.
The expression "substantially preserves the immunological capabilities of the immunogenic polypeptide", as used herein, means that the variant shows at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%), at least 90%>, at least 95% or 100% of the ability of the immunogenic polypeptide for inducing an adaptive immune response (i.e. a humoral or cell-mediated immune response), if injected on its own or with adjuvants.
The term "treat" or "treatment", as used herein, refers to the administration of an immunogenic composition of the invention or of a medicament containing it to control the progression of the disease before or after clinical signs have appeared. Control of the disease progression is understood to mean the beneficial or desired clinical results that include, but are not limited to, reduction of the symptoms, reduction of the duration of the disease, stabilization of pathological states (specifically to avoid additional deterioration), delaying the progression of the disease, improving the pathological state and remission (both partial and total). The control of progression of the disease also involves an extension of survival, compared with the expected survival if treatment was not applied.
The term "vaccine", as used herein, refers to a substance or composition that establishes or improves immunity to a particular disease by inducing an adaptive immune response including an immunological memory. A vaccine typically contains an agent that resembles a disease-causing microorganism or a part thereof (e.g. a polypeptide). Vaccines can be prophylactic or therapeutic.
The term "variant", as used herein, refers to all those amino acid sequences derived from any of SEQ ID NOs 1-16 by means of modifications or mutations, including substitutions, preferably conservative substitutions, insertions or non-terminal deletions, affecting one or more amino acids and which substantially preserves the immunogenic capabilities of the immunogenic polypeptide.
The term "vector", as used herein, refers to a nucleic acid molecule, linear or circular, that comprises a segment according to the nucleic acid of interest operably linked to additional segments that provide for its autonomous replication in a host cell of interest or according to the expression cassette of interest.
2. Immunogenic polypeptides of the invention
In a first aspect, the invention relates to an immunogenic polypeptide having an amino acid sequence comprising the sequences SEQ ID NOs 1-16 or variants of said SEQ ID NO: 1-16, wherein each of said variants has a length of at least 8 amino acids, with the provisos that said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or the variants thereof.
In a particular embodiment, the immunogenic polypeptide of the first aspect has an amino acid sequence comprising SEQ ID NO: 49.
In a second aspect, the invention relates to an immunogenic polypeptide having an amino acid sequence comprising at least one sequence selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof or a fragment thereof, wherein said fragment has a length of at least 8 amino acids, with the provisos that:
i) said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or a variant or a fragment thereof, and
ii) when the immunogen comprises only one sequence selected from the group consisting of SEQ ID NOs 1-16, then this sequence is not selected from the group consisting of SEQ ID NO: 3, 5, 6 and 16.
Preferably, the variant according to the first and second aspects is equivalent to its related sequence and derives from a different HIV strain or is an artificial HIV sequence. Equivalent in this respect means different in one or more amino acid residues, but corresponding to the same sequence (e.g. determined by the position in the genome or sequence similarity). In other words, in a preferred embodiment, the variant is a "naturally occurring variant", which refers to nucleic acid sequences derived from an HIV genome of a presently or formerly circulating virus and can be identified from existing databases (e.g. GenBank and Los Alamos sequence databases). The sequence of circulating viruses can also be determined by molecular biology methodologies. See Brown T, "Gene Cloning" (Chapman & Hall, London, GB, 1995); Watson R, et al., "Recombinant DNA", 2nd Ed. (Scientific American Books, New York, NY, US, 1992); Sambrook J, et al, "Molecular Cloning. A Laboratory Manual" (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, US, 1989). Preferably, a variant of any of SEQ ID NOs 1-16 has an amino acid sequence identity of at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% to its corresponding (i.e. SEQ ID NOs 1-16). Examples of algorithms suitable for determining percent sequence identity and sequence similarity are BLAST and BLAST 2.0 algorithms. See Altschul S, et al, Nuc. Acids Res. 1977; 25:3389-3402 and Altschul S, et al, J. Mol. Biol. 1990; 215:403-410. The BLAST and BLAST 2.0 programs can be used to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. See http://blast.ncbi.nlm.nih.gov/blast.cgi, January 2012.
Variants may also contain one or more modified amino acid residues (e.g. residues that are modified by the attachment of substituent groups), or one or more unnatural amino acids such as beta amino acids.
Methods for determining the extent of the cellular response are known in the art. Any method suitable for assessing the stimulation of T cells in response to an Ag can be used. The procedures described below provide a few examples of suitable methods:
1) Enzyme-linked immunospot (ELISpot): non-adherent cells from pre-culture wells are transferred to a plate, which has been coated with the desired anti- cytokine capture antibodies (Abs; e.g. anti-IFN, -IL-10, -IL-2, -IL-4). Revelation is carried out with biotinylated secondary Abs and standard colorimetric or fluorimetric detection methods such as streptavidin-alkaline phosphatase and NBT-BCIP and the spots counted. ELISpot readouts are then expressed as spot- forming cells (SFC)/ 106 input cells.
2) Supernatant cytokine assay: cytokines released in the culture supernatant are measured by different techniques, such as enzyme-linked immunosorbent assays (ELISA), BD cytometric bead array, Biorad Bio-Plex assay and others.
3) HLA Class I tetramers: with this procedure, Ag-reactive T cells recognizing specific peptide epitopes are detected, using either commercially available reagents (e.g. MHC Class I Dexamers, Immudex, Copenhagen, DK) or in- house generated ones (e.g. Novak E, et αί, J. Clin. Invest. 1999; 104:R63- R67).
4) HLA Class II tetramers: with this procedure, Ag-reactive T cells recognizing specific peptide epitopes are detected, using either commercially available reagents (e.g. MHC Class II Ultimers™, Prolmmune Ltd, Oxford, GB) or in- house generated ones (e.g. Novak, 1991, supra).
5) Upregulation of activation markers (e.g. CD69, CD25, CD137): with this procedure, Ag-specific T cell responses are detected by their differential expression of activation markers exposed on the membrane following Ag- recognition.
6) Cytokine capture assays: this system is a valid alternative to the ELISpot to visualize Ag-specific T cells according to their cytokine response (Miltenyi Biotec GmbH, Bergisch Gladbach, DE). In addition, it allows the direct sorting and cloning of the T cells of interest.
7) CD 154 assay: this procedure is limited to detection of Ag-specific CD4+ T cells. See Chattopadhyay P, et al, Nat. Med. 2005; 11 : 1113-11117 and Frentsch M, et al, Nat. Med. 2005; 11 : 1118-1124.
8) CD 107 assay: this procedure allows the visualization of Ag-specific CD8+ T cells with cytotoxic potential. See Betts M, et al, J. Immunol. Methods 2003; 281 :65-78.
9) CFSE dilution assay: this procedure detects Ag-specific T cells (CD4+ and CD8+) according to their proliferation following Ag recognition. See
Mannering S, et al, J. Immunol. Methods 2003; 283: 173-183.
Methods for determining the extent of the humoral response of a variant are known in the art. Any method suitable for assessing the stimulation of T cells in response to an Ag can be used. Examples of suitable methods include, but are not limited to, detecting or quantitating the relative amount of an antibody, which specifically recognizes an antigenic or immunogenic agent in the sera of a subject who has been treated with an immunogenic polypeptide or variant relative to the amount of the antibody in an untreated subject. Antibody titers can be determined using standard assays such as enzyme-linked immunosorbent assay (ELISA), Single Radial Immunodiffusion Assay (SRID), or Enzyme Immunoassay (ETA).
In a preferred embodiment, the variant of any of SEQ ID NOs 1-16 is a fragment of said sequence(s).
In specific embodiments, ancestral viral sequences are determined for the env genes of HIV-1 subtypes B or C, or for the gag genes of subtypes B or C. In other embodiments, the ancestral viral sequence is determined for other HIV genes or polypeptides, such as pol or the auxiliary genes or polypeptides. In yet another embodiment, the viral sequence is determined by consensus or center-of-tree techniques.
In a preferred embodiment, the HIV is a group M HIV. Group M is the predominant circulating HIV-1 group. It has been divided into subtypes, denoted with letters, and sub-subtypes, denoted with numerals. Subtypes Al, A2, A3, A4, B, C, D, E, Fl , F2, G, H, J, and K are currently recognized. HIV-1 subtypes, also called clades, are phylogenetically linked strains of HIV-1 that are approximately the same genetic distance from one another; in some cases, subtypes are also linked geographically or epidemio logically. Genetic variation within a subtype can be 15 to 20 percent or more, whereas variation between subtypes or divergent members of the same subtype is usually 25 to 35 percent. Advances in full-genome sequencing of HIV have led to the identification of circulating and unique recombinant forms (CRFs and URFs, respectively). These are the result of recombination between subtypes within a dually infected person, from whom the recombinant forms are then passed to other people. The recombinant progeny are classified as circulating recombinant forms if they are identified in three or more people with no direct epidemiologic linkage; otherwise they are described as unique recombinant forms.
In one embodiment, said immunogen has an amino acid sequence comprising at least one sequence selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, wherein said proviso ii) is: when the immunogen comprises only one sequence selected from the group consisting of SEQ ID NOs 1-16, then this sequence is not selected from the group consisting of SEQ ID NOs 1-16.
In a preferred embodiment, said immunogen comprises at least two, at least three, or at least four sequences selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, wherein said proviso ii) is: when the immunogen comprises only two, three, or four sequences selected from the group consisting of SEQ ID NOs 1- 16, then not all of these sequences are selected from the group consisting of SEQ ID NO: 3, 5, 6 and 16. In another embodiment, said immunogen has an amino acid sequence comprising at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten sequences selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, wherein said proviso ii) is: when the immunogen comprises only two, three, four, five, six, seven, eight, nine or ten sequences selected from the group consisting of SEQ ID NOs 1-16, then not all of these sequences are selected from the group consisting of SEQ ID NOs 1-16.
In a preferred embodiment, the immunogen according to the first aspect comprises the sequences according to SEQ ID NOs 1-16 or variants thereof in the order In one embodiment, the invention relates to the immunogen of the first aspect wherein at least two sequences are adjoined by an amino acid linker.
In another embodiment, the invention relates to the immunogen of the second aspect, wherein, if said immunogen comprises at least two sequences selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, said sequences are adjoined by an amino acid linker.
In a preferred embodiment of the immunogens of both the first and second aspect, the linker has the amino acid sequence A, AA or AAA. In a another embodiment, when the C-terminal residue of the sequence located N-terminally with respect to the linker or the N-terminal residue of the sequence located C-terminally is an alanine residue, the linker can be shortened so that an AAA sequence is formed in the junction region between adjoining sequences. Thus, in a preferred embodiment, if the C-terminal residue of the sequence located N-terminally with respect to the linker is an alanine or if the N-terminal residue of the sequence located C-terminally with respect to the linker is alanine, the linker has the sequence AA. In another embodiment, if the C- terminal residue of the sequence located N-terminally with respect to the linker and the N-terminal residue of the sequence located C-terminally with respect to the linker are both alanine, then the linker as the sequence A.
In another embodiment, said immunogens further comprise a secretion signal peptide at the N-terminus, wherein said signal peptide preferably enhances secretion of the immunogen from cells expressing said immunogen. A preferred secretion signal peptide is derived from GMCSF (granulocyte macrophage colony- stimulating factor), preferably followed by a valine to increase stability. The sequence of the GMCSF signal peptide is preferably: MWLQSLLLLGTVACSIS (SEQ ID NO: 46) or MWLQSLLLLGTVACSISV (SEQ ID NO: 47).
In another embodiment, said immunogens further comprise optionally a peptide tag. The peptide tag can be located at the N-terminus between the signal peptide and the immunogenic polypeptide or, preferably, can be located at the C-terminus before the stop codon.
Preferably, said tag is a FLAG peptide. The FLAG system utilizes a short, hydrophilic 8-amino acid peptide, which is fused to the recombinant protein of interest. The FLAG peptide includes the binding site for several highly specific ANTI-FLAG monoclonal antibodies (Ml, M2, M5; Sigma- Aldrich Corp., Saint Louis, MO, US), which can be used to assess expression of the protein of interest on material from transfected cells. Because of the small size of the FLAG peptide tag, it does not shield other epitopes, domains, or alter the function, secretion, or transport of the fusion protein generally. Preferably, said FLAG peptide has the sequence DYKDDDDKL (SEQ ID NO: 48).
In a preferred embodiment, said tag is only for expression analysis and purification of the immunogen and it is removed before using it to elicit an immune response.
In another embodiment, the invention relates to said immunogens, wherein said amino acid sequence comprises at least one antiretroviral resistance mutation site.
The mutation can occur at any site within the viral genome. Preferably, the mutation occurs in the region encoding the integrase, the protease or the reverse transcriptase genes.
Mutants within the integrase that confer resistance to integrase inhibitors include, without limitation, T66, E92, F121, E138, G140, Y143, S147, Q148, S153, N155, E157 and R263 within SEQ ID NO: 1 and a combination thereof. In a preferred embodiment, the mutation is selected from the group consisting of mutations E92Q, G 140S, G 140A and Y143R in the integrase protein and their combinations.
Mutants within the protease associated with protease inhibitor (PI) resistance include major protease, accessory protease, and protease cleavage site mutations. See Shafer R, et ah, AIDS Rev. 2008; 10(2):67-84. Seventeen largely non-polymorphic positions are of the most clinical significance, including L231, L241, D30N, V321, L33F, M461/L, 147/V/A, G48V/M, 150L/V, F53L, 154V/T/A/L/M, G73S/T, L76V, V82A/T/F/S, 184V/A/C, N88D/S, L90M. Accessory protease mutations include the polymorphic mutations L101/V, 113V, K20R/M/I, M36I, D60E, I62V, L63P, A71V/T, V77I, and 193L and the non-polymorphic mutations L10F/R, VI 11, E34Q, E35G, K43T, K45I, K55R, Q58E, A71I/L, T74P/A/S, V751, N83D, P79A/S, 185V, L89V, T91 S, Q92K and C95F.
In another embodiment, the antiretroviral resistance mutation site is located in the reverse transcriptase, resulting in a resistance to nucleoside reverse transcriptase inhibitor (NRTI) or to non-nucleoside reverse transcriptase inhibitor (NNRTI). The NRTI resistance mutations include Ml 84V, thymidine analog mutations (TAMs), mutations selected by regimens lacking thymidine analogs (Non-TAMs), and multi- nucleoside resistance mutations (Multi-NRTI mutations) and many recently described non-polymorphic accessory mutations. Altogether, Ml 84V, non-thymidine-analog- associated mutations such as K65R and L74V, and the multi-nucleoside resistance mutation Q151M act by decreasing NRTI incorporation. Thymidine analog mutations, the T69 insertions associated with multi-nucleoside resistance, and many of the accessory mutations facilitate primer unblocking. See Shafer, 20008, supra. Ml 84V is the most commonly occurring NRTI resistance mutation. The most common drug- resistant amino acid mutations are M41L, D67N, K70R, L210W, T215Y/F and K219QE. The most common mutations in patients developing viro logic failure while receiving a non-thymidine analog containing NRTI backbone (Non-TAMs) include Ml 84V alone or Ml 84V in combination with K65R or L74V. Other Non-TAMs mutations include K65N, K70E/G, L741, V75T/M, Y115F. Amino acid insertions at codon 69 generally occur in the presence of multiple TAM, and in this setting are associated with intermediate resistance to 3TC and FTC and high-level resistance to each of the remaining NRTI. Q151 M is a 2-bp mutation (CAG.fwdarw.ATG) that is usually accompanied by two or more of the following mutations: A62V, V751, F77L, and F116Y. The Q151M complex causes high-level resistance to ZDV, d4T, ddl, and ABC, and intermediate resistance to TDF, 3TC, and FTC. See Shafer R, et al., AIDS Rev. 2008; 10(2):67-84
NNTRI resistance mutations include, without limitation, the primary NNRTI resistance mutations (K103N/S, V106A/M, Y181C/I/V, Y188L/C/H, and G190A/S/E), the NNRTI resistance secondary mutations (L1001, K101P, P225H, F227L, M230L, and K238T) and rate mutations (V179F, F227C and L2341).
Minor non-polymorphic mutations- A98G, K101 E, V 1081, and V 179D/E are common NNRTI resistance mutations that reduce susceptibility to nevirapine and efavirenz about 2-fold to 5-fold.
Miscellaneous nonnucleoside reverse transcriptase inhibitor resistance mutations, such as K101Q, 1135T/M, V1791, and L2831, reduce susceptibility to nevirapine and efavirenz by about twofold and may act synergistically with primary NNRTI resistance mutations. Other mutations such as L74V, H221Y, K223E/Q, L228H/R, and N3481 are selected primarily by NRTI, yet also cause subtle reductions in NNRTI susceptibility.
Preferably, said antiretroviral resistance mutation site is located in any of SEQ ID NOs 9-11. More preferably, said antiretroviral resistance mutation site is amino acid residue 8 of SEQ ID NO: 9, wherein the amino acid Leu is substituted by the amino acid Met.
In another embodiment, the variant or fragment has a length of 8 to 40 amino acids, more preferably a length of 11 to 27 amino acids. Preferably, said variant or fragment does not comprise an amino acid linker adjoining any of SEQ ID NOs 1-16. Furthermore, it is preferred that the C-terminal amino acid of said variant or fragment is neither G, P, E, D, Q, N, T, S, nor C, as these residues do not form a C terminal anchor for HLA class I restricted T cell epitopes generally.
In a most preferred embodiment, said variant or fragment is selected from the group consisting of the peptides according to SEQ ID NOs 17-45.
Further, it is envisaged that said variant or fragment is combined with or fused to a heat shock protein. The present invention also relates to a fusion protein comprising said variant or fragment and a heat shock protein. Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO.
In another embodiment, the variant or fragment is a variant or fragment according to the first and second aspects. Preferably, said variant or fragment does not comprise an amino acid linker adjoining any of SEQ ID NOs 1-16. Furthermore, it is preferred that the C-terminal amino acid of said variant or fragment is neither G, P, E, D, Q, N, T, S, nor C, as these residues do not form a C terminal anchor for HLA class I restricted T cell epitopes generally.
In a most preferred embodiment, said variant or fragment is selected from the group consisting of the peptides according to SEQ ID NOs 17-45.
Further, it is envisaged that said variant or fragment is combined with or fused to a heat shock protein. The present invention also relates to a fusion protein comprising said variant or fragment and a heat shock protein. Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO.
3. Nucleic acids, vectors, viruses and cells of the invention In a third aspect, the present invention relates to a nucleic acid encoding for the immunogen of the first aspect, and to an expression cassette, a vector, a virus and a cell comprising said nucleic acid.
Preferably, said nucleic acid is a polynucleotide, referring to single-stranded or double-stranded polymers of nucleotide monomers (nucleic acids), including, but not limited to, 2'-deoxyribonucleotides (DNA) and ribonucleotides (R A) linked by internucleotide phosphodiester bond linkages. The polynucleotides of the invention encode the immunogen of the invention without substantially comprising additional regions of the HIV genome.
In one embodiment, said nucleic acid is codon optimized. In a preferred embodiment, the nucleic acid is codon optimized for expression in humans. Codon- optimized nucleic acids for use according to the present invention can be prepared by replacing the codons of the nucleic acid encoding the immunogen by "humanized" codons (i.e. the codons are those that appear frequently in highly expressed human genes). See Andre S, et ah, J. Virol. 1998; 72: 1497-1503. In a preferred embodiment, said codon-optimized nucleic acid has the sequence according to SEQ ID NO: 50.
The nucleic acid of the third aspect may require cutting with restriction enzymes in order to it ligate into a vector. This procedure could entail the removal of various terminal nucleotides (e.g. 1, 2, or 3). As such, in one embodiment, the invention relates to said nucleic acid, wherein it has been cut at each end with a restriction enzyme.
In another embodiment, the present invention relates to an expression cassette comprising the nucleic acid of the third aspect, a promoter sequence and a 3'-UTR and optionally a selection marker. Preferably, the promoter sequence is a human cytomegalovirus (CMV) promoter or an early-late p7.5 promotor sequence. Preferably, the 3'-UTR is a bovine growth hormone (BGH) poly- A. The optional selection marker is an antibiotic resistance gene (e.g. kanamycin, ampicilin, tetracycline, spectinomycin) preferably.
In yet another embodiment, the present invention relates to an expression vector comprising the nucleic acid or the expression cassette of the third aspect.
In one embodiment, the vector is an expression vector. Thus, suitable vectors according to the present invention include prokaryotic vectors, such as pUC18, pUC19, and Bluescript plasmids and derivatives thereof, like the mpl8, mpl9, pBR322, pMB9, ColEl, pCRl and RP4 plasmids; phages and shuttle vectors, such as pSA3 and pAT28 vectors; expression vectors in yeasts, such as 2-micron plasmid type vectors; integration plasmids; YEP vectors; centromeric plasmids and analogues; expression vectors in insect cells, such as the vectors of the pAC series and of the pVL series; expression vectors in plants, such as vectors of the pIBI, pEarleyGate, pAVA, pCAMBIA, pGSA, pGWB, pMDC, pMY, pORE series and analogues; and expression vectors in superior eukaryotic cells either based on viral vectors (e.g. MVA, adenoviruses, viruses associated to adenoviruses, retroviruses and lentiviruses) as well as non-viral vectors, such as the pSilencer 4.1-CMV (Ambion®, Life Technologies Corp., Carslbad, CA, US), pcDNA3, pcDNA3.1/hyg pHCMV/Zeo, pCR3.1, pEFl/His, pIND/GS, pRc/HCMV2, pSV40/Zeo2, pTRACER-HCMV, pUB6/V5-His, pVAXl, pZeoSV2, pCI, pSVL and pKSV-10, pBPV-1, pML2d and pTDTl vectors.
In a particular embodiment the expression vector is a mammalian expression vector comprising a mammalian promoter and a polyadenylation site. Preferably, the promoter is the human cytomegalovirus (CMV) promoter. Preferably, the polyadenylation site is the bovine growth hormone (BGH) polyadenylation site. The mammalian expression vector can be modified to optimize vector replication in bacteria. The mammalian expression vector can further comprise a selection gene, for example, a gene coding a protein conferring resistance to an antibiotic. In a particular embodiment, the mammalian expression vector comprises a kanamycin resistance gene
In other particular embodiment, the expression vector is a viral vector, preferably a Modified Vaccine Ankara (MVA) virus vector.
In another embodiment, the present invention relates to a virus containing the nucleic acid of the third aspect. Suitable viruses are safe, have low toxicity and are genetically stable. Non-limiting examples are retroviruses, particularly poxviruses such as MVA, lentiviruses, adenoviruses and adeno-associated viruses (AAVs).
In a further particular preferred embodiment the present invention relates to a recombinant Modified Vaccinia virus Ankara (MVA) comprising in a polynucleotide or gene construct encoding the immunogenic polypeptides of the invention. Modified Vaccinia Ankara (MVA) virus is related to the vaccinia virus, a member of the genera orthopoxvirus in the family of poxviridae. MVA has been generated by 516 serial passages on chicken embryo fibroblasts of the Ankara strain of vaccinia virus (CVA). See Mayr A, et al, Infection 1975; 3:6-14 and Sutter G, et al, US 6,440,422 and CH 568,392. MVA viruses are publicly available (e.g. ATCC accession number VR-1508). MVA is distinguished by its attenuation (e.g. diminished virulence and limited ability to reproduce infectious virions in certain mammalian cells), while maintaining good immunogenicity and full capacity to replicate and produce infectious virions in avian cells. Suitable MVA strains include strains with enhanced safety due to i) capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF), but no capability of reproductive replication in a human cell line, as in the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarcinoma cell line HeLa; ii) failure to replicate in a mouse model that is incapable of producing mature B and T cells and as such is severely immune compromised and highly susceptible to a replicating virus; and iii) induction of at least the same level of specific immune response in vaccinia virus prime/vaccinia virus boost regimes when compared to DNA-prime/vaccinia virus boost regimes. A suitable attenuated MVA strain in the strain referred to as MVA-BN. See Chaplin P, et al, WO2002042480, ECACC accession number V00083008.
In another embodiment, the present invention relates to a cell comprising the nucleic acid, the expression cassette, the expression vector, or the virus of the third aspect. Cells to be used can be of any cell type, including both eukaryotic cells and prokaryotic cells. Preferably, the cells include prokaryotic cells, yeast cells, or mammalian cells. Preferred examples of mammalian cells are COS cells, HeLa cells, HEK 293T cells or cells isolated from a patient (e.g. a HIV patient). 4. Compositions of the invention
In a fourth aspect, the present invention relates to a composition comprising a variant or fragment according to the first and second aspects and a heat shock protein. Immunogenic compositions can be prepared, for instance, as injectables such as liquid solutions, suspensions, and emulsions. Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO. Furthermore, the invention relates to a pharmaceutical composition comprising an immunogen, nucleic acid, expression cassette, vector or cell according to the invention or a composition according to the fourth aspect and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical compositions and the composition of the fourth aspect may be used as a vaccine, as laid out below.
5. Vaccine of the invention
In another aspect, the present invention relates to a vaccine comprising the immunogen of the first and second aspects, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the third aspect or the composition of the fourth aspect.
In a preferred embodiment, said vaccine is capable of generating cellular and humoral responses. More preferably, the vaccine generates a cytotoxic T cell response. A cytotoxic T cell or cytotoxic T lymphocyte (CTL) assay can be used to monitor the cellular immune response following subgenomic immunization with a viral sequence against homologous and heterologous HIV strains. See Burke S, et ah, J. Inf. Dis. 1994; 170: 1110-1119 and Tigges M, et al, J. Immunol, 1996; 156:3901-3910. Conventional assays utilized to detect T cell responses include, for instance, proliferation assays, lymphokine secretion assays, direct cytotoxicity assays and limiting dilution assays. For example, antigen-presenting cells that have been incubated with a peptide can be assayed for their ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be cells such as peripheral blood mononuclear cells (PBMCs) or dendritic cells (DCs). Alternatively, mutant non-human mammalian cell lines that are deficient in their ability to load MHC class I molecules with internally processed peptides and that have been transfected with the appropriate human MHC class I gene, can be used to test the capacity of a peptide of interest to induce in vitro primary CTL responses. PBMCs can be used as the responder cell source of CTL precursors. The appropriate antigen-presenting cells are incubated with the peptide after which the protein- loaded antigen-presenting cells are incubated with the responder cell population under optimized culture conditions. Positive CTL activation can be determined by assaying the culture for the presence of CTL that kill radiolabeled target cells, both specific peptide-pulsed targets as well as target cells expressing endogenously processed forms of the antigen from which the peptide sequence was derived. For example, the target cells can be radiolabeled with 51Cr and cytotoxic activity can be calculated from radioactivity released from the target cells. Another suitable method allows the direct quantification of antigen-specific T cells by staining with fluorescein-labeled HLA tetrameric complexes. See Altman J, et al., Proc. Natl. Acad. Sci. USA 1993; 90: 10330-10334 and Altman J, et al, Science 1996; 274:94-96. Other relatively recent technical developments include staining for intracellular lymphokines and interferon release assays or ELISpot assays.
In one embodiment, the vaccine of the fourth aspect further comprises one or more adjuvants or heat shock proteins.
Adjuvants are defines as above. Preferred heat shock proteins are HsplO, Hsp20, Hsp30, Hsp40, Hsp60, Hsp70, Hsp90, gp96, or HsplOO. 6. Therapeutic methods
In a preferred embodiment, the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention can be used in the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
Thus, in another aspect, the invention relates to the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention for use in the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
In another aspect, the invention relates to the use of the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention for the manufacture of a medicament for the prevention or treatment of an HIV infection or a disease associated with an HIV infection. In another aspect, the invention relates to a method for the prevention or treatment of an HIV infection or a disease associated with an HIV in a subject in need thereof comprising the administration to said subject of the immunogenic polypeptide according to the invention, the nucleic acid of the invention, the expression cassette of the invention, the expression vector of the invention, the virus of the invention, the cell of the invention or the vaccine according to the invention for the manufacture of a medicament for the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
In a particular embodiment, the immunogenic peptide, the nucleic acid, the expression cassette the expression vector, the virus, the cell or the vaccine for use according to the invention, comprises the sequential administration of :
i) a first immunogenic peptide of any of claims 1-11, nucleic acid of any of claims 12-14, expression cassette of claim 15, expression vector of claim 16, virus of any of claims 17-18, cell of claim 19 or vaccine of claim 20 and
ii) a second immunogenic peptide of any of claims 1-11, nucleic acid of any of claims 12-14, expression cassette of claim 15, expression vector of claim 16, virus of any of claims 17-18, cell of claim 19 or vaccine of claim 20.
In a particular embodiment, the first the first immunogenic peptide, nucleic acid, expression cassette, expression vector, virus, cell or vaccine are different from the second immunogenic peptide, nucleic acid, expression cassette, expression vector, virus, cell or vaccine. Preferably, it is first administered an expression vector according to the invention followed by the administration of a Modified Vaccinia Ankara virus according to the invention.
In a particular embodiment, the first expression vector according to the invention is administered at least twice, preferably at least three times.
The beneficial prophylactic or therapeutic effect of vaccine in relation to HIV infection or AIDS symptoms include, for example, preventing or delaying initial infection of an individual exposed to HIV; reducing viral burden in an individual infected with HIV; prolonging the asymptomatic phase of HIV infection; maintaining low viral loads in HIV infected patients whose virus levels have been lowered via anti- retroviral therapy (ART); increasing levels of CD4 T cells or lessening the decrease in CD4 T cells, both HIV-1 specific and non-specific, in drug naive patients and in patients treated with ART, increasing the breadth, magnitude, avidity and functionality of HIV specific CTL, increasing overall health or quality of life in an individual with AIDS; and prolonging life expectancy of an individual with AIDS. A clinician can compare the effect of immunization with the patient's condition prior to treatment, or with the expected condition of an untreated patient, to determine whether the treatment is effective in inhibiting AIDS.
Preferably, said disease is AIDS, ARC or an HIV opportunistic disease. Non- limiting examples for HIV opportunistic diseases are Burkitt's lymphoma, candidiasis in the bronchi, trachea, lungs, or esophagus, cervical cancer, coccidioidomycosis (disseminated or outside the lungs), cryptococcosis (outside the lungs), cryptosporidiosis (in the intestines lasting for more than 1 month), cytomegalovirus infection (outside the liver, spleen, or lymph nodes), cytomegalovirus retinitis (with loss of vision), HIV encephalopathy, herpes simplex lesions lasting for more than one month, herpes simplex in the bronchi, lung, or esophagus, histoplasmosis (disseminated or outside the lungs), immunoblastic lymphoma, invasive cervical carcinoma (cancer), isosporiasis in the intestines lasting for more than one month, Kaposi's sarcoma, lymphoma (primary in the brain), Mycobacterium avium complex (disseminated or outside the lungs), Mycobacterium kansasii (disseminated or outside the lungs), Mycobacterium tuberculosis (disseminated or outside the lungs), Pneumocystis carinii pneumonia, pneumonia (recurrent in 12 month period), progressive multifocal leukoencephalopathy (PML), salmonella septicemia (recurrent), toxoplasmosis (in the brain), wasting syndrome and any other disease resulting from an infection facilitated by a compromised immune system in an HIV-infected patient.
The vaccine of the invention may be useful for the therapy of HIV-1 infection. While all animals that can be afflicted with HIV-1 or their equivalents can be treated in this manner (e.g. chimpanzees, macaques, baboons or humans), the immunogenic compositions of the invention are directed particularly to their therapeutic uses in humans. Often, more than one administration may be required to bring about the desired therapeutic effect; the exact protocol (dosage and frequency) can be established by standard clinical procedures. The present invention further relates to preventing or reducing symptoms associated with HIV infection. These include symptoms associated with the minor symptomatic phase of HIV infection, including, for example, shingles, skin rash and nail infections, mouth sores, recurrent nose and throat infection and weight loss. In addition, further symptoms associated with the major symptomatic phase of HIV infection include, for instance, oral and vaginal thrush (candidiasis), persistent diarrhea, weight loss, persistent cough and reactivated tuberculosis or recurrent herpes infections, such as cold sores (herpes simplex). Other symptoms of full-blown AIDS which can be treated in accordance with the present invention include, for instance, diarrhea, nausea and vomiting, thrush and mouth sores, persistent, recurrent vaginal infections and cervical cancer, persistent generalized lymphadenopathy (PGL), severe skin infections, warts and ringworm, respiratory infections, pneumonia, especially Pneumocystis carinii pneumonia (PCP), herpes zoster (or shingles), nervous system problems, such as pains, numbness or "pins and needles" in the hands and feet, neurological abnormalities, Kaposi's sarcoma, lymphoma, tuberculosis or other similar opportunistic infections.
Beneficial effects of the invention include, for example, preventing or delaying initial infection of an individual exposed to HIV, reducing viral burden in an individual infected with HIV, prolonging the asymptomatic phase of HIV infection, maintaining low viral loads in HIV infected patients whose virus levels have been lowered via anti- retroviral therapy (ART), increasing levels of CD4 T cells or lessening the decrease in CD4 T cells, both HIV-1 specific and non-specific, in drug na'ive patients and in patients treated with ART, increasing the breadth, magnitude, avidity and functionality of HIV specific CTL, increasing overall health or quality of life in an individual with AIDS and prolonging life expectancy of an individual with AIDS. A clinician can compare the effect of immunization with the patient's condition prior to treatment, or with the expected condition of an untreated patient, or in a clinical trial of individuals treated and untreated with the vaccine to determine whether the treatment is effective in inhibiting AIDS.
The immunogenic compositions can be designed to introduce the nucleic acids or expression vectors to a desired site of action and release it at an appropriate and controllable rate. Methods of preparing controlled-release formulations are known in the art. For example, controlled release preparations can be produced by the use of polymers to complex or absorb the immunogen or immunogenic composition. A controlled-release formulation can be prepared using appropriate macro molecules (e.g. polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) known to provide the desired controlled release characteristics or release profile. Another possible method to control the duration of action by a controlled-release preparation is to incorporate the active ingredients into particles of a polymeric material (e.g. polyesters, polyamino acids, hydrogels, polylactic acid, polyglycolic acid, copolymers of these acids, or ethylene vinylacetate copolymers). Alternatively, instead of incorporating these active ingredients into polymeric particles, it is possible to entrap these materials into microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and polymethylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (e.g. liposomes, albumin microspheres, microemulsions, nano-particles, nanocapsules) or in macroemulsions. See in Voller A, et ah, Eds., "New Trends and Developments in Vaccines (University Park Press, Baltimore, MD, US, 1978) and Gennaro A, Ed., "Remington's Pharmaceutical Sciences", 18th Ed. (Mack Publishing Co., Easton, PA, US, 1990).
Suitable dosages of the nucleic acids and expression vectors of the invention (collectively, the immunogens) in the immunogenic composition of the invention can be readily determined by those of skill in the art. For example, the dosage of the immunogens can vary depending on the route of administration and the size of the subject. Suitable doses can be determined by those of skill in the art, for example by measuring the immune response of a subject, such as a laboratory animal, using conventional immunological techniques, and adjusting the dosages as appropriate. Such techniques for measuring the immune response of the subject include but are not limited to, chromium release assays, tetramer binding assays, IFN ELISPOT assays, IL-2 ELISPOT assays, intracellular cytokine assays, and other immunological detection assays. See Harlow E, Lane D, "Antibodies: A Laboratory Manual" (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, US, 1988).
The immunogenic compositions can be administered using any suitable delivery method including, but not limited to, intramuscular, intravenous, intradermal, transcutaneous, intranasal, mucosal (e.g. intrarectal, intravaginal, oral), and topical delivery. Such techniques are well known in the art. More specific examples of delivery methods are intramuscular injection, intradermal injection, and subcutaneous injection. However, delivery need not be limited to injection methods. Further, delivery of DNA to animal tissue has been achieved by cationic liposomes direct injection of naked DNA into animal muscle tissue or intradermal injection of DNA using "gene gun" or electroporation technology. See Watanabe M, et al, Mol. Reprod. Dev. 1994; 38:268- 274, Charnock- Jones D, et al, WO 1996020013, Robinson H, et al, Vaccine 1993: 11 :957-960, Hoffman S, et al, Vaccine 1994; 12(16): 1529-1533; Xiang Z, et al, Virology 1994; 199: 132-140, Webster R, et al, Vaccine 1994; 12: 1495-1498, Davis H, et al, Vaccine 1994; 12: 1503-1509, Davis H, et al, Hum. Mol. Gen. 1993; 2: 1847- 1851, and Johnston S, et al, Meth. Cell Biol. 1994; 43:353-365. Delivery can be accomplished via a mucosal surface such as the anal, vaginal or oral mucosa also. 7. Kit of the invention
In anotheraspect, the present invention relates to a kit comprising the immunogen of the first aspect, the peptide or variant thereof of the second aspect, the nucleic acid, the expression cassette, the expression vector, the virus or the cell of the fourth aspect, or the vaccine of the fourth aspect. These kits provide the materials necessary for carrying out the application described in the present invention. The kit could also be in the form of a patch.
In addition, the kit may comprise a packaging, which allows maintaining the reagents within determined limits. Suitable materials for preparing such packings include glass, plastic (e.g. polyethylene, polypropylene, polycarbonate), bottles, vials, paper, or sachets. The kit of the invention can additionally contain instructions for using the components contained therein, in particularly those constituting the hemostatic patch of the invention. Said instructions can be found in the form of printed material or in the form of an electronic support which can store instructions such that they can be read by a subject, such as electronic storage media (e.g. magnetic disks, tapes), or optical media (e.g. CD-ROM, DVD). The media can additionally or alternatively contain internet websites providing said instructions. GENERAL PROCEDURES
1. T cell immunogen design The following approach was followed for the design of the HIV OLPs of the invention.
Experimental (interferon gamma ELISpot) screening of 232 HIV infected untreated individuals using a consensus clade B peptide set revealed regions of the viral proteome that were predominantly targeted by subjects with superior HIV control. See Frahm N, et al, J. Virol. 2004; 78:2187-2200; Mothe B, et al, J. Transl. Med. 201 1; 9(1):208. The overall test peptide set consisted of 410 18mer overlapping peptides spanning the entire viral proteome. Of these, 26 OLPs were identified where the group of OLP responders had a significantly (p<0.05 uncorrected for multiple comparison) reduced viral load compared to the group of OLP non-responders (i.e. individuals that did not react to these OLPs in the interferon gamma ELISpot assay). These beneficial OLPs had a protective ratio (PR of >1) and were located in HIV Gag protein (n= 10), in Pol (n=12), and in Vif (n=3) and Nef (n=l) proteins of the virus. Of the 26 OLPs, 15 were partially overlapping. See Table 1.
Table 1
Median Median
Protective
OLP Protein viral load in viral load in
Protein OLP clade B consensus sequence Ratio p-value No. sub-unit OLP OLP non- (PR)*
responders responders
3 Gag pl7 EKIRLRPGGKKKYKLKHI 22947 39014 1.053 0.037
6 Gag pl7 ASRELERFAVNPGLL 15380 43189 1.107 0.001
7 Gag pl7 ERFAVNPGLLETSEGCR 25939 38974 1.040 0.049
10 Gag pl7 QLQPSLQTGSEELRSLY 16285 37237 1.085 0.031
12 Gag pl7 SLYNTVATLYCVHQRIEV 23855 371 13 1.044 0.037
23 Gag p24 AFSPEVIPMFSALSEGA 22947 371 13 1.048 0.036
31 Gag p24 IAPGQMREPRGSDIA 3563 35483 1.281 0.028
34 Gag p24 STLQEQIGWMTNNPPIPV 6127 37360 1.207 0.002
48 Gag p24 ACQGVGGPGHKARVLAEA 12975 35755 1.107 0.041
60 Gag pl5 GKIWPSHKGRPGNFLQSR 16266 36434 1.083 0.044
75 Nef WLEAQEEEEVGFPVRPQV 13407 37360 1,108 0.026
76 Nef EVGFPVRPQVPLRPMTYK 59618 29855 0.937 0.001
84 Nef NYTPGPGIRYPLTFGWCF 55402 30538 0.945 0.006
85 Nef RYPLTFGWCFKLVPV 69890 29903 0.924 0.002 Median Median
Protective
OLP Protein viral load in viral load in
Protein OLP clade B consensus sequence Ratio p-value No. sub-unit OLP OLP non- (PR)*
responders responders
90 Nef SLHGMDDPEKEVLVWKF 89687 32650 0.91 1 0.042
159 Pol Protease KM1GG1GGF1KVRQYDQ1 14736 36434 1.094 0.020
160 Pol Protease F1KVRQYDQ1L1E1CGHK 3682 35755 1.277 0.031
161 Pol Protease Q1L1E1CGHKA1GTVLV 91 17 35483 1.149 0.050
163 Pol Protease LVGPTPVN11GRNLLTQ1 25965 45637 1.055 0.007
171 Pol RT LVE1CTEMEKEGK1SK1 1865 35483 1.391 0.014
181 Pol RT LDVGDAYFSVPLDKDFRK 65858 32871 0.937 0.041
195 Pol RT LRWGFTTPDKKHQKEPPF 5624 371 13 1.219 0.006
196 Pol RT DKKHQKEPPFLWMGYELH 10103 35483 1.136 0.044
210 Pol RT E1QKQGQGQWTYQ1Y 18155 35483 1.068 0.045
222 Pol RT PPLVKLWYQLEKEP1VGA 412599 34640 0.808 0.030
230 Pol RT 1HLALQDSGLEVN1V 85102 341 17 0.919 0.030
237 Pol RT VYLAWVPAHKG1GGNEQV 85102 341 17 0.919 0.029
240 Pol RT SAG1RKVLFLDG1DKA 1 16902 32761 0.891 0.019
269 Pol Integrase TKELQKQ1TK1QNFRVYY 6629 35755 1.192 0.030
270 Pol Integrase TK1QNFRVYYRDSRDPLW 18171 37360 1.073 0.019
271 Pol Integrase YYRDSRDPLWKGPAKLLW 25939 35755 1.032 0.043
276 Pol Integrase K11RDYGKQMAGDDCVA 6629 35755 1.192 0.021
279 Vpr GPQREPYNEWTLELLEEL 60222 32650 0.944 0.042
307 Env gpl20 DLNNNTNTTSSSGEKMEK 179419 341 17 0.863 0.044
31 1 Env gpl20 1RDKVQKEYALFYKLDVV 179419 32871 0.860 0.008
314 Env gpl20 YRL1SCNTSV1TQACPKV 58206 31273 0.943 0.008
315 Env gpl20 SV1TQACPKVSFEP1P1H 6101 1 32871 0.944 0.034
320 Env gpl20 TNVSTVQCTHG1RPVV 341587 34640 0.820 0.034
355 Env gpl20 VAPTKAKRRVVQREKRAV 161602 341 17 0.870 0.042
399 Env gp41 V1EVVQRACRA1LH1PRR 388089 34640 0.812 0.026
405 Vif VKHHMY1 SGKAKGWF YRH 16458 37237 1.084 0.021
406 Vif GKAKGWFYRHHYESTHPR 16458 37237 1.084 0.022
424 Vif TKLTEDRWNKPQKTKGHR 10319 36434 1.137 0.014
* PR values in bold indicate PR > 1 , i.e. OLP -responses seen more frequently in individuals with reduced viral loads.
In order to build a continuous immunogen sequence, the 26 OLPs were aligned and assembled to a total of 16 segments, ranging from 1 1-78 amino acids in length. The precise starting and end positions of these segments were based on analyzing residues in up and down-steam of the identified 26 OLPs and was based on a number of considerations that were applied to the different flanking sites. These considerations included:
1) OLP immunogenicity data
2) Conserved region reactivity data Extension or chopping segments for inclusion/exclusion of good or bad known epitopes
4) CD4 epitope coverage
5) HLA coverage
6) Sequence variability (2010 consensus and HBX2 defined epitopes)
7) Multivariate OLP analyses
8) Creation of new epitope/self epitope
9) Maintenance of natural sequence though not included beneficial OLP
10) Introduction of changes to avoid epitope recognition and
11) Avoid forbidden residues (G,P,E,D,Q,N,T,S or C)
This protocol resulted in the design of SEQ ID NO: 1 to SEQ ID NO potential immunogens.
2. Vectors
Sequences SEQ ID NO: 1 to SEQ ID NO: 16 were linked with single, dual or triple alanine amino acids between segments to ensure optimal processing and to avoid premature epitope digestion.
Then, the linked segments were used as HIV T cell immunogen sequences for inclusion in DNA and MVA vectors. For the delivery of the immunogens using either soluble peptides only or in combination with heat shock proteins, shorter overlapping peptides (median length 23 residues) were designed that span the 16 segments, not including the triple AAA linkers. These OLPs were generated in a way that helped avoid forbidden residues at the C-terminal end (important for optimal epitope presentation on HLA class I molecules. See SEQ ID NO: 17 to SEQ ID NO: 45, , January 2012). These overlapping peptides range in length from 11-27 amino acids.
3. T cell immunogen The T cell immunogen has been designed as a polypeptide and assembled from
16 segments of the HIV-1 genome of varying size (between 11 to 78 aa) unified by triple alanine linkers. Description of the regions included: T cell
HIV-1 Position SEQ ID
immunogen Length
protein (HXB2) NO:
segments
Seg-1 78 pl7 17-94 1
Seg-2 14 p24 30-43 2
Seg-3 11 p24 61-71 3
Seg-4 60 p24 91-150 4
Seg-5 14 p24 164-177 5
Seg-6 15 p24 217-231 6
Seg-7 27 p2p7plp6 63-89 7
Seg-8 55 protease 45-99 8
Seg-9 17 RT 34-50 9
Seg-10 55 RT 210-264 10
Seg-11 34 RT 309-342 11
Seg-12 34 Integrase 210-243 12
Seg-13 17 Integrase 266-282 13
Seg-14 23 Vif 25-50 14
Seg-15 19 Vif 166-184 15
Seg-16 13 Nef 56-68 16
Total length: 529 (including A, AA or AAA linkers)
4. Inclusion of a leader sequence
Signal peptides are generally highly hydrophobic amino acid sequences (15 to 60 amino acids long) of proteins that must cross through membranes to arrive at their functioning cellular location. By binding to signal recognition particles, these sequences direct nascent protein-ribosome complexes to a membrane where the protein is inserted during translation. Signal peptides direct translational uptake of the protein by various membranes (e.g. endoplasmic reticulum, mitochondria, chloroplast, peroxisome). Leader signal sequences on non-membrane proteins are ultimately removed by specific peptidases. Some signal peptides used include MCP-3 chemokine, for promoting secretion and attraction of antigen presenting cells; a catenin (CATE)-derived peptide for increased proteasomal degradation; and the lysosomal associated protein, LAMPl for targeting the MHC II compartment. See Rosati M, et al., Proc. Natl. Acad. Sci. USA 2009; 106: 15831-15836.
In the present design, the signal peptide from GMCSF (granulocyte macrophage colony-stimulating factor) was introduced at the amino -terminus of the immunogen to enhance secretion of the immunogen from expressing cells, followed by a valine to increase stability. The sequence of the GMCSF signal peptide is:
MWLQSLLLLGTVACSIS (SEQ ID NO: 46)
5. Inclusion of a tag for in-vitro expression experiments For the purpose of assessing expression in transfected cells, the immunogen sequence first included a FLAG peptide on the C-terminal region, before the stop codon, was:
DYKDDDDKL (SEQ ID NO: 48)
The FLAG system utilizes a short, hydrophilic 8 -amino acid peptide, which is fused to the recombinant protein of interest. The FLAG peptide includes the binding site for several highly specific ANTI-FLAG monoclonal antibodies (Ml, M2, M5; Sigma- Aldrich Corp., Saint Louis, MO, US), which can be used to assess expression of the protein of interest on material from transfected cells.
Because of the small size of the FLAG peptide tag, it does not shield other epitopes, domains, or alter the function, secretion, or transport of the fusion protein generally. This sequence was removed afterwards for the mice immunogenicity assay. The FLAG tag is removed from the final immunogen (298H) before immunization.
6. Description of the T cell immunogen The T cell immunogen has the following sequence (SEQ ID NO: 49):
M W L Q S L L L L G T V A C S I S | (E K I R L R P G G K K K Y K L K H I V W A S R E L E R F A V N P G L L E T S E G C R Q I L G Q L Q P S L Q T G S E E L K S L Y N T V A T L Y C V H Q K I E V)si A A A (K A F S P E V I P M F S A L)S2 A A (G H Q A A M Q M L K E) S3 A A A (I A P G Q M R E P R G S D I A G T T S T L Q E Q I G W M T N N P P I P V G E I Y K R W I I L G L N K I V R M Y S P T S I ) s4 A A A (Y V D R F Y K T L R A E Q A) s5 A (A C Q G V G G P G H K A R V L)se A A A (C T E R Q A N F L G K I W P S H K G R P G N F L Q S R)s7 A A A (K M I G G I G G F I K V R Q Y D Q I L I E I C G H K A I G T V L V G P T P V N I I G R N L L T Q I G C T L F)sg A A A (L V E I C T E M E K E G K I S K I)s9 A A A (L R W G F T T P D K K H Q K E P P F L W M G Y E L H P D K W T V Q P I V L P E K D S W T V N D I Q K L V G K L) Sio A A A (I L K E P V H G V Y Y D P S K D L I A E I Q K Q G Q G Q W T Y Q I Y)Sn A A A ( K E L Q K Q I T K I Q N F R V Y Y R D S R D P L W K G P A K L L W)si2 A A A (K I I R D Y G K Q M A G D D C V A) si3 A A (V K H H M Y I S K K A K G W F Y R H H Y E S T H P R)si4 A A A (V K L T E D R W N K P Q K T K G H R)sis A A (A W L E A Q E E E E V G F) Si6 D Y K D D D D K L wherein,
the GMCSF signal peptide is shown underlined, the valine immediately following the signal sequence is highlighted, the single, dual or triple A (AAA) linkers are shown in bold, the FLAG epitope (removed in the final construct for in- vivo studies) is shown in italics and the different segments are shown in brackets as follows: Segment number HIV polypeptide HIV gene
(-) si pl7 (Seg-l)
(•••) s2-6 p24 (Seg-2 to Seg-6) gag
(•••) S7 p2p7plp6 (Seg-7)
(. . .) S8 Prot (seg-8)
(. . .) S9-11 RT (Seg-9 to Seg-11) Pol
(— ) S12-13 Int (Seg-12 and Seg-13 J-
(· - ·) S14-15 Vif (Seg-14 and Seg-15) Vif
(•••) si6 Nef (Seg-16) Nef
7. Nucleotide sequence codon optimization
The T cell immunogen sequence was translated into a RNA/codon-optimized nucleotide sequence to enhance expression and secretion (Mr. Gene GmbH, Regensburg, DE). Codon optimization was based on introducing multiple nucleotide changes to destroy the previously identified RNA processing, inhibitory and instability sequences in the mRNA without affecting the encoded protein. See Schwartz S, et ah, J. Virol. 1992; 66(12): 7176-7182. This process can also include the elimination of predicted splice sites (score>0.4) from coding sequences by appropriate codon changes, to minimize the possibility of splicing.
As a result of the nucleotide changes indicated above, the final GC-content of the T cell immunogen was 63%. The complete codon-optimized nucleotide sequence of the immunogen is (SEQ ID NO: 50):
ATGTGGCTCC AGAGCCTGCT ACTCCTGGGG ACGGTGGCCT GCAGCATCTC GfifGAGAAG
61 ATCCGGCTGC GGCCAGGCGG AAAGAAGAAG TACAAGCTGA AGCACATCGT CTGGGCCTCG
121 AGGGAGCTGG AGCGGTTCGC GGTGAACCCG GGACTTCTGG AGACGTCGGA GGGGTGCAGG
1 81 CAGATCCTCG GCCAGCTGCA GCCCTCTCTG CAAACGGGGT CTGAGGAGCT GAAGAGCCTG
2 41 TACAACACGG TGGCGACCCT CTACTGCGTC CACCAGAAGA TCGAGGTGGC AGCGGCCAAG
301 GCGTTCTCGC CGGAGGTCAT CCCCATGTTC TCGGCGCTGG CAGCTGCCGG ACACCAGGCC
361 GCGATGCAGA TGCTGAAGGA GGCCGCTGCG ATCGCACCGG GCCAGATGAG GGAGCCACGC
421 GGTTCCGACA TCGCGGGAAC CACCTCGACG CTCCAGGAGC AGATCGGATG GATGACGAAC
4 81 AACCCGCCAA TCCCGGTCGG GGAGATCTAC AAGCGGTGGA TCATCCTCGG GCTGAACAAG
541 ATCGTCCGGA TGTACAGCCC GACGTCGATC GCTGCGGCAT ACGTTGACCG GTTCTACAAG 601 ACCCTGAGGG CCGAGCAGGC AGCGGCCTGC CAGGGGGTCG GTGGACCAGG GCACAAGGCC
661 CGAGTGCTCG CGGCCGCATG CACGGAGCGG CAGGCGAACT TCCTGGGGAA GATCTGGCCG
721 TCGCACAAGG GCCGACCGGG AAACTTCCTC CAGTCTCGCG CAGCGGCTAA GATGATCGGA
781 GGCATCGGAG GCTTCATCAA AGTCCGTCAG TACGACCAGA TCCTCATCGA GATCTGCGGG
841 CACAAGGCGA TCGGAACCGT GCTCGTCGGC CCAACGCCCG TGAACATCAT CGGCCGCAAC
901 CTGTTAACGC AGATCGGCTG CACCCTCAAC TTCGCCGCAC TAGTGGAGAT CTGCACGGAG
961 ATGGAGAAGG AGGGCAAGAT ATCGAAGATC GCGGCAGCTC TGAGGTGGGG CTTCACCACG
1021 CCGGACAAGA AGCACCAGAA GGAGCCGCCA TTCCTGTGGA TGGGATACGA GCTGCACCCG
1081 GACAAGTGGA CCGTGCAGCC CATCGTCCTG CCGGAGAAGG ACTCGTGGAC GGTGAACGAC
1141 ATCCAGAAGC TCGTGGGGAA GCTGGCGGCA GCCATCCTCA AGGAGCCCGT CCACGGGGTG
1201 TACTACGACC CCTCTAAGGA CCTGATCGCG GAGATCCAGA AGCAGGGGCA GGGTCAGTGG
1261 ACCTACCAGA TCTACGCAGC AGCAACCAAG GAGCTGCAGA AGCAGATCAC GAAGATCCAG
1321 AACTTCCGCG TATACTACCG CGACTCGCGG GACCCCCTGT GGAAGGGCCC TGCGAAGCTT
1381 CTCTGGGCAG CCGCGAAGAT CATCCGGGAC TACGGCAAGC AGATGGCGGG CGACGACTGC
1441 GTGGCCGCAG CGGTGAAGCA CCATATGTAC ATCTCGAAGA AGGCGAAGGG CTGGTTCTAC
1501 AGACACCACT ACGAGTCCAC CCACCCCAGG GCAGCTGCGG TGACGAAGCT GACGGAGGAC
1561 CGGTGGAACA AGCCCCAGAA GACGAAGGGT CACCGGGCGG CTGCATGGCT GGAGGCTCAG
1621 GAGGAGGAGG AGGTGGGCTT CGATTACAAG GACGATGACG ACAAGCTGtq ataa wherein the sequence encoding GMCSF signal peptide is underlined, the valine codon immediately downstream of the sequence encoding the signal sequence is shown highlighted, the sequence encoding the immunogenic polypeptide is shown in standard letters, the sequence encoding the Flag tag is shown in italics and the tga and taa stop codons are shown in lower case.
8. Cloning strategy
The codon-optimized T cell immunogen was cloned into the mammalian expression plasmid BV5, which consists of a modified CMV basic plasmid backbone optimized for growth in bacteria that harbors the human cytomegalovirus (CMV) promoter, the bovine growth hormone (BGH) polyadenylation site and the kanamycin resistance gene— lacking the Xho site. The cloning steps were as follows:
1) In a first step, an amino acid change from Leu to Meth was introduced into the synthesized T cell immunogen -one including the FLAG epitope at RT 41 position (segment 9) to cover one of the major antiretroviral resistance mutations site. The T cell immunogen gene (starting vector) was cloned in a spectomycin resistance harboring plasmid. A PCR-generated segment covering the RT M41 change was inserted into the T cell immunogen as Spel/Hindlll. Competent cells DH108B were used for transformation and were grown on LB-spectomycin media. The resulting plasmid was named HIV AC AT RT M41. Insertion of the point mutation was confirmed by PCR sequencing using sense and antisense primers covering the segment 9 sequence.
2) In a second step, the HIV AC AT RT M41 gene was inserted to the BV5 plasmid that lacks the Xho site in kanamycin resistance gene as Sall/EcoRI, by ligation of the vector and the gel purified digested HIV AC AT RT M41 fragment. Competent cells DH108B were used for transformation and were grown in LB-Kan media. Resulting plasmid name was 297H (GMCSF- HIVACAT-FLAG). Insertion of the gene was confirmed by restriction digestion and PCR sequencing using sense (from the CMV promoter) and antisense primers (from the polyA BGH region).
3) In a third step, the epitope for the FLAG tag was removed from the 297H plasmid by BstEII-EcoRI digestion and insertion the annealed primers 298H Plus and 298H Minus:
298HPlus
GTCACCGGGCGGCTGCATGGCTGGAGGCTCAGGAGGAGGAGGAG GTGGGCTTCtgataaG (SEQ ID NO: 51)
298H Minus
aattCttatcaGAAGCCCACCTCCTCCTCCTCCTGAGCCTCCAGCCATGC AGCCGCCCG (SEQ ID NO: 52)
The resulting plasmid was named 298H GMCSF-HIVACAT, accession number DSM 25555). See Fig 1. Removal of the FLAG tag was confirmed by PCR sequencing using antisense primers (from the polyA BGH region).
Example 1
In-vitro expression studies Several transient transfections were performed to assess expression, localization and stability of the HI VAC AT T cell immunogen.
Briefly, l x lO6 human 293 cells in complete DMEM plus 10% fetal bovine serum (FBS) were plated on to 60mm tissue culture dishes and allowed to adhere overnight. HEK 293 cells were transfected by CaPhosphate DNA co -precipitation with a total of 7μg of DNA (lOOng or 250ng of the 297H GMCSF-HIVACAT-FLAG plasmid DNA, 50 ng of GFP expressing plasmid pFRED143 topped up to 7 μg with Bluescript DNA).
6 hours after transfection the medium were replaced with 3 ml of DMEM supplemented with 2% of FCS. After 24 and 48 hrs the cells and the supernatants were collected in 0.5X RIPA.
Protein expression was analyzed by Western immunoblots. 1/250 of the total of the cell extracts and supernatants were loaded. The proteins were resolved by electrophoresis on 10% sodium dodecyl sulfate polyacrylamide gels (Nu-Page Bis-Tris, NuPAGE, Invitrogen, Life Technologies Corp., Carlsbad, CA, US) and transferred onto nitrocellulose membranes.
297H plasmid was detected upon probing the membranes with horseradish peroxidase-conjugated anti-FLAG monoclonal antibody (Sigma-Aldrich Corp., Saint Louis, MO, US) at a 1 :3.000 dilution.
Bands were visualized using ECL. Membranes were imaged on a ChemiDoc
XRS +.
Positive controls were used and included plasmid DNA encoding for clade B p55 Gag, which also harbored the FLAG tag.
Cell extracts from transient transfections using the 298H plasmid (encoding for the HIVACAT T cell immunogen without the FLAG-tag) were probed with human serum from an HIV-1 infected subject at a 1 :3.000 dilution followed by a horseradish peroxidase-conjugated human anti-IgG, dilution 1 : 10.000.
297H and 298H plasmids stably (same estimated amount at 24h and 48h) expressed the HIVACAT T cell immunogen construct, which was visualized at the cell extract compartment. There was no evidence of secretion of the construct. Example 2
Cellular response in mice
A stock of 1ml (2mg/ml) of 298H GMCSF-HIVACAT DNA was produced endofree for in vivo studies in mice.
Immunogenicity of the HIVACAT T cell immunogen was evaluated in 6-8 weeks old female C57BL/6 mice (Charles River Labs, Inc., Frederick, MD, US).
20 μg and 5μg of DNA was delivered intramuscularly by electroporation using the Inovio system (Inovio Pharmaceuticals, Inc., Blue Bell, PA, US) in the left and right quadriceps (20 μg/50 μΐ per dose, 25 μΐ per site) at week 0 and 4. Mice were sacrificed 2 weeks after the last immunization. Mice splenocytes and serum were harvested for immunogenicity studies. Control DNAs used were:
1) 114H p55 gag clade B: expresses full gag protein;
2) 132H NTV: expresses a chimaeric protein of nef, tat and vif;
3) 133H pol: expresses full pol protein; and
4) BV4 CMV-kan-Basic: SHAM control, similar DNA plasmid backbone without any expressed transgene.
35 mice were used in the experiment, pooling 5 mice per group. Distribution of the immunization per group was as follows:
Groups Inocula Delivery Dose DNA/Site n number (quadriceps)
1 114 p55 gag clade B I.M. Inovio 20μ§ 25mL/site 5
2 114 p55 gag clade B + I.M. Inovio 20μ§ 25mL/site 5
132H NTV + 133 pol each
3 298H GMCSF-HIVACAT I.M. Inovio 20μ§ 25mL/site 5
4 114 p55 gag clade B I.M. Inovio 5μ§ 25mL/site 5
5 114 p55 gag clade B + I.M. Inovio 5μ§ 25mL/site 5
132H NTV + 133 pol each
6 298H GMCSF-HIVACAT I.M. Inovio 5μ§ 25mL/site 5
7 (SHAM) BV4 CMVKan-Basic I.M. Inovio 20μ§ 25mL/site 5 Cellular immune responses were characterized on a first step using intracellular cytokine staining (ICS) in pooled splenocytes (cells from the 5 mice belonging to group) and using a pool of overlapping peptides covering all gag, pol, nef, tat and vif proteins.
Briefly, pooled isolated mouse splenocytes from each group of mice were incubated at a density if 2xl06 cells/ml, in 1 ml co-culture overnight, in the presence of peptide pools (15-mers, overlapping by 1 laa covering clade B gag, consensus B pol and NL43 nef, tat and vif sequences, 1 μg/ml each peptide, total of about 12 hours, 1 hour without Golgi stop to prevent cytokine secretion). Surface immunostaining was performed with CD3- allophycocyanin-Cy7, CD4-PerCP, CD8-Pacific Blue (BD Biosciences, Inc., Franklin Lakes, NJ, US). Intracellular cytokine staining was performed using interferon gamma-FITC antibody (BD Biosciences, Inc., Franklin Lakes, NJ, US) after permeabilization.
From the first immunogenicity analyses, both 20 μg and 5 μg of DNA in C57BL/6 mice did generate detectable interferon gamma -+ responses to full gag, pol and nef-tat-vif peptide pools. See Fig. 2a. Distribution of CD4+ and CD8+ responses is shown. See Fig. 2b.
At an individual mice level, responses were deconvo luted using frozen splenocytes stimulated with 8 pools of peptides to cover the protein subunits included in the immunogen in an interferon gamma ELISpot assay.
ELISpot assay was performed by using mouse interferon gamma ELISpot kit (ALP) (Mabtech AB, Stockholm, SE) following the manufacturer's instructions with minor modifications. For all assays, mice splenocytes were added at an input cell number of 4xl05 cells/well in 140μ1 of Rosewell Park Memorial Institute medium 1640 with 10% fetal bovine serum in 96-well polyvinylidene plates (Millipore Corp., Bedford, MA, US) alone or with HIV-1- specific peptide pools (14μg/ml final concentration for each peptide) for 16hours at 37°C in 5% C02. Eight pools of peptides, each containing between 2 and 12 peptides of 18 amino acids based on the 2001 consensus-B sequence were pooled into the different protein subunits (gag-pl7, gag- p24, gag-p2p7plp6, pol-RT, pol-protease, pol-integrase, vif and nef) spanning the segments included in the HI VAC AT T cell immunogen. See http://hiv- web.lanl.gov/content/hiv-db/CONSENSUS/M_GROUP/Consensus.html, January 2012. The HIV peptides pools used in mice immunized with DNAs expressing full gag, pol, nef, tat and vif proteins, consisted of 18-mers peptides with an overlap of 11 residues spanning the complete gag (6 pools, 11 peptides/each), pol (8 pools, 16 or 17 peptides/each), nef (2 pools, 13 o 14 peptides/each), tat (1 pool, 12 peptides) and vif (2 pools, 12 peptides/each) proteins.
Concavalin A (Sigma-Aldrich Corp., Saint Louis, MO, US), at 5 mg/ml, was used as a positive control. The plates were developed with one-step 5-bromo-4-chloro- 3-indolyl phosphate/Nitroblue Tetrazolium (BCIP/NBT, Bio-Rad Laboratories, Inc., Irvine, CA, US). The spots on the plates were counted using an automated ELISPOT reader system (CTL Analyzers LLC, Cleveland, OH, US) using ImmunoSpot software and the magnitude of responses was expressed as spot forming cells (SFC) per million input splenocytes. The threshold for positive responses was defined as at least 5 spots per well and responses exceeding the "mean number of spots in negative control wells plus 3 standard deviations of the negative control wells" and "three times the mean of negative control wells", whichever was higher.
1) Dominance of interferon gamma responses developed in mice immunized with plasmids encoding for the entire gag, pol, nef, tat and vif proteins was towards regions outside the HI VAC AT T cell immunogen covered segments (median ratio of responses targeting HIVACAT immunogen regions/total gag+pol+nef+tat+vif was 0.26 (range 0.17-0.42)) and did not differ among groups immunized with high dose (20μg) or low dose (5 μg) of DNA. See Fig. 3
2) Median breadth of responses to protein subunits included in the HIVACAT T cell immunogen sequence was 4 (range 2-5) in mice immunized with 20μg of HIVACAT vs 2 responses (range 1-3) in mice immunized with 20μg of plasmids encoding for entire proteins (ns) with no significant differences in the magnitude of responses. Six out of the eight protein subunits were at least targeted once in the mice immunized with the HIVACAT T cell immunogen. See Fig.4. HIVACAT Mice making a
Mice making a
T cell Pool Peptides/ response
HIV-1 protein response (groups immunogen number pool (groups Gag- HIVACAT) segments Pol-NTV)
Seg-1 gag- l7 HTI-pooll 10 0/10 3/10
Seg-2 gag-p24
Seg-3 gag-p24
Seg-4 gag-p24 HTI-pool2 12 10/10 10/10
Seg-5 gag-p24
Seg-6 gag-p24
Seg-7 gag-p2p7plp6 HTI-pool3 3 0/10 0/10
Seg-8 pol-protease HTI-pool4 6 4/10 7/10
Seg-9 pol-RT
Seg-10 pol-RT HTI-pool5 11 5/10 9/10
Seg-11 pol-RT
Seg-12 pol-integrase
HTI-pool6 4 0/10 0/10
Seg-13 pol-integrase
Seg-14 vif
HTI-pool7 4 3/10 2/10
Seg-15 vif
Seg-16 nef HTI-pool8 2 0/10 1/10
4) Dominance of responses in mice immunized with plasmids encoding the full proteins of gag, pol, nef, tat and vif was 89% driven mainly towards gag, while in mice immunized with the HIVACAT T cell immunogen at high doses was more balanced to all protein components (gag, pol, vif and nef) contained in the immunogen. See Fig. 5.
Example 3
Humoral response in mice
Humoral responses were first analyzed in pooled mice sera. Binding antibodies to p24, p37 and p55 were detected by western immunoblot by using cell extracts from HEK 293cells transfected with the lmg of gag expression vectors separated on 12% SDS-Page and probing the membranes with pooled sera from mice (at a 1 : 100 dilution). Antibody titers to gag p24 were measured by ELISA. Serial 4-fold dilutions of the pooled serum samples were assessed and the optical absorbance at 450nm was determined (Advanced Bioscience Lab, Inc., Kensington, MD, US). The binding titers were reported as the highest dilution scoring positive having a value higher than the average plus 3 standard deviations obtained with control sera from the mice immunized with SHAM DNA.
a) From the first humoral immunogenicity analyses, the HIVACAT T cell immunogen induced binding antibody responses to gag p55, p37 and p24 detectable by Western blot in the group of mice immunized with 20 μg. See Fig 6.
b) Binding antibodies to p24 were quantified by ELISA. The endpoint titers of gag-p24 specific binding antibody from the mice that received the plasmids described were determined by ELISA from individual serial 4-fold diluted pooled serum samples. In the high dose group of mice immunized with HIVACAT T cell immunogen at a titre of 1 :4,000 which were lower to the titers detected in mice immunized with the full gag construct. No binding antibodies to p24 were measurable in the low dose group. See Fig 7a. At an individual mice level, in house developed gag p55 ELISA using the HIV- 1IIIB pr55 gag recombinant protein (Cat. No. 3276, NIH Reagent Program, Bethesda, MD, US) was performed with mice sera at 1 : 100 dilution. Low levels of antibody were detectable in 2 out of 3 mice immunized with the high dose of the immunogen. See Fig 7b.
Example 4
Heterologous prime/boost in-vivo immunogenicity in mice
MATERIAL AND METHODS
Preparation ofpDNA-HIVA CAT and MVA-HIVA CA T vaccines
The codon-optimized T cell immunogen was cloned into the mammalian expression plasmid BV5, which consists of a modified CMV basic plasmid backbone optimized for growth in bacteria that harbors the human cytomegalovirus (CMV) promoter, the bovine growth hormone (BGH) polyadenylation site and the kanamycin resistance gene— lacking the Xho site. The plasmid DNA for mice immunizations was prepared using the Endo-Free Megaprep (Qiagen) and stored -80°C until use. A recombinant MVA expressing the HIVACAT gene was made as described previously{Letourneau, 2007 #235; Nkolola, 2004 #321 } . Briefly, chicken embryo fibroblast (CEF) cells grown in Dulbeco's Modified Eagle's Medium supplemented with 10% FBS, penicillin/streptomycin and glutamine (DMEM 10) were infected with parental MVA at MOI 1 and transfected using Superfectin (Quiagen) with 3ug of pDNA-HIVACAT carrying the β-galactosidase gene as a marker. Two days later, the total virus was harvested and used to re-infect CEF cells. MVA was subjected to five round of plaque purification, after which a master virus stock was grown, purified on a 36%o sucrose cushion, tittered and stored at -80°C until use.
In-vivo immunogenicity in C57BL/6 mice.
For heterologous prime/boost in-vivo immunogenicity experiments in mice, groups of five 6-to 8-weeks-old female C57BL/6 (Harlan Laboratories Ltd., Barcelona, Spain) were used. Mice were primed intramuscularly with 100μg of pDNA-HIVACAT (2 or 3 vaccinations) followed by a 10A6 pfu of MVA-HIVACAT boost (groups: 2xDNA, 3xDNA, 2xDNA + 1 MVA and 3xDNA + 1 MVA respectively) All vaccinations were separated by three weeks.
All mice were sacrificed two weeks after the last vaccination in each experiment. Mice splenocytes and serum were harvested for immunogenicity studies. Spleens were removed and pressed individually through a cell strainer (Falcon) using a 5 -ml syringe rubber punger. Following rbc lysis, splenocytes were washed and resuspended in RPMI 1640 supplemented with 10%> FCS, penicillin/streptomycin (R10) and frozen until use.
All animal procedures and care were approved by a local Ethical Comitte.
Overlapping peptides and distribution of peptide pools
To evaluate immunogenicity of the heterologous regimens were pDNA or MVA expressing only the HIVACAT T-cell immunogen and to rule out immunogenicity of the potential junctional epitopes an overlapping peptide set of 147 peptides of 15 amino acids in length (overlapping by 11 residues) spanning the entire HIVACAT T-cell immunogen (including the leader sequence and linkers regions) was newly synthesized using 9-Fluorenylmethyloxycarbonyl (Fmoc)- chemistry. Peptides were distributed in 18 different pools, according to protein subunits and segments of the immunogen (1 pool for the signal peptide sequence, n=4 peptides; 7 pools for Gag, n=8-l l peptides/each; 7 pools for Pol, n=5-l l peptides/each; 2 pools for Vif, n=6-8 peptides/each and 1 pool for Nef, n=2 peptides) Results are presented grouped by IFNy responses specific for the eight protein subunits (Gag pi 7, Gag p24, Gag p2p7plp6, Pol-Protease, Pol-RT, Pol-Integrase, Vif and Nef)
Murine INFy ELISPOT assay
ELISpot assay was performed by using mouse IFNy ELISpot kit (ALP)
(Mabtech AB, Stockholm, SE) following the manufacturer's instructions with minor modifications. For all assays, frozen mice splenocytes were first thawed and rested for 5h 37°C in RIO before use. Cells were added at an input cell number of 4xl05 cells/well in 140μ1 of RIO in 96-well polyvinylidene plates (Millipore Corp., Bedford, MA, US) alone or with HIV-1- specific peptide pools (14μg/ml final concentration for each peptide) for 16hours at 37°C in 5% C02. Concavalin A (Sigma-Aldrich Corp., Saint Louis, MO, US), at 5 mg/ml, was used as a positive control. The plates were developed with one-step 5-bromo-4-chloro-3-indolyl phosphate/Nitroblue Tetrazolium (BCIP/NBT, Bio-Rad Laboratories, Inc., Irvine, CA, US). The spots on the plates were counted using an automated ELISPOT reader system (CTL Analyzers LLC, Cleveland, OH, US) using ImmunoSpot software and the magnitude of responses was expressed as spot forming cells (SFC) per million input splenocytes. The threshold for positive responses was defined as at least 5 spots per well and responses exceeding the "mean number of spots in negative control wells plus 3 standard deviations of the negative control wells" and "three times the mean of negative control wells", whichever was higher.
RESULTS
In these experiments as no mice were immunized using plasmids encoding for full proteins, a second set of overlapping peptides matching the exact immunogen sequence was synthesized and used for immunogenicity comparisons. Three intramuscular (i.m.) immunisations with 100μg of pDNA-HIVACAT were able to induce frequencies of IFNy responses in all mice that were comparable to the frequencies of IFNy responsed induced by immunisations with the electroporation Inovio system. However, two pDNA i.m. vaccinations were found to be immunogenic in only three animals (60%) compared to 100% of animals inducing a responses after three pDNA i.m. immunizations. Interestingly, MVA-HIVACAT vaccine was able to boost responses both in breadth and magnitude, (Fig 8B) in the two groups analyzed, but did just significantly increase the magnitude of responses when mice had previously been primed with three doses of pDNA-HIVACAT (Fig 8B and 8C). As seen in the previous EP experiments, a balanced and broad response to most of all the protein- subunits included in the immunogen was observed in all animals, without a clear pattern of dominance among them. No nef or gag-pl5 specific responses were detected in the studied mice (Fig 8D).
•k
While the invention is described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.
All publications mentioned hereinabove are hereby incorporated in their entirety by reference.

Claims

An immunogenic polypeptide having an amino acid sequence comprising the sequences SEQ ID NOs 1-16 or variants of said SEQ ID NO: 1-16, wherein each of said variants has a length of at least 8 amino acids, with the provisos that said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or the variants thereof.
The immunogenic polypeptide according to claim 1 wherein at least two sequences are connected by an amino acid linker, wherein said linker results in the formation of an AAA sequence region in the junction region between adjoining sequences.
The immunogenic polypeptide according to any of claims 1 or 2 having an amino acid sequence comprising SEQ ID NO: 49.
An immunogenic polypeptide having an amino acid sequence comprising at least one sequence selected from the group consisting of the SEQ ID NOs 1-16 or a variant thereof wherein said variant has a length of at least 8 amino acids, with the provisos that:
i) said amino acid sequence does not comprise any sequence stretches derived from the HIV genome of a length of 8 or more amino acids other than an amino acid sequence according to any of SEQ ID NOs 1-16 or the variant thereof, and
ii) when the immunogen comprises only one sequence selected from the group consisting of SEQ ID NOs 1-16, then this sequence is not selected from the group consisting of SEQ ID NO: 3,
5, 6 and 16.
The immunogen according to claim 4 wherein, if said immunogen comprises at least two sequences selected from the group consisting of the SEQ ID NOs 1-16 or variants thereof, said sequences are connected by an amino acid linker, wherein said linker results in the formation of an AAA sequence region in the junction region between adjoining sequences.
6. The immunogen according to any one of claims 1-5, wherein said amino acid sequence comprises at least one antiretroviral resistance mutation site, and, preferably, wherein said antiretroviral resistance mutation site is located in any of SEQ ID NOs 9-l l.
7. The immunogen according to any one of claims 1-6, further comprising a signal peptide at the N-terminus.
8. The immunogen according to any one of claims 1-7, wherein said variant has a length of 8 to 40 amino acids, more preferably, a length of 11 to 27 amino acids.
9. The immunogen according to any one of claims 1-8, wherein the C-terminal amino acid of said variant is neither G, P, E, D, Q, N, T, S, nor C.
10. The immunogen according to any one of claims 1-9, wherein said variant is selected from the group consisting of the peptides according to SEQ ID NOs 17- 45.
11. The immunogen according to any one of claims 1-10, wherein said variant is fused to a heat shock protein.
12. A nucleic acid encoding for the immunogen of any of claims 1-11.
13. A nucleic acid according to claim 12 which has been codon optimized for expression in human cells.
14. The nucleic acid of claim 13, wherein said nucleic acid has the sequence according to SEQ ID NO 50.
15. An expression cassette comprising the nucleic acid of any of claims 12-14, a promoter sequence, a 3'-UTR and, optionally, a selection marker.
16. An expression vector comprising the nucleic acid of any of claims 12-14 or the expression cassette of claim 15.
17. A virus comprising the nucleic acid of any of claims 12-14.
18. The virus according to claim 17, wherein said virus is a Modified Vaccine Ankara virus.
19. A cell comprising the nucleic acid of any of claims 12-14, the expression cassette of claim 15, the expression vector of claim 16 or the virus of any of claims 17-18.
20. A vaccine comprising an immunogenic polypeptide according to any of claims 1 to 11 and one or more adjuvants.
21. The immunogenic peptide of any of claims 1-11, the nucleic acid of claims 12-14, the expression cassette of claim 15, the expression vector of claim 16, the virus of any of claims 17-18, the cell of claim 19 or the vaccine according to claim 20 for use in medicine.
22. The immunogenic peptide of any of claims 1-11, the nucleic acid of claims 12-14, the expression cassette of claim 15, the expression vector of claim 16, the virus of any of claims 17-18, the cell of claim 19 or the vaccine according to claim 20 for use in the prevention or treatment of an HIV infection or a disease associated with an HIV infection.
23. The immunogenic peptide, the nucleic acid the expression cassette the expression vector, the virus, the cell or the vaccine for use according to claim 22, said use comprising the sequential administration of :
i) a first immunogenic peptide of any of claims 1-11, nucleic acid of any of claims 12-14, expression cassette of claim 15, expression vector of claim 16, virus of any of claims 17-18, cell of claim 19 or vaccine of claim 20 and ii) a second immunogenic peptide of any of claims 1-11, nucleic acid of any of claims 12-14, expression cassette of claim 15, expression vector of claim 16, virus of any of claims 17-18, cell of claim 19 or vaccine of claim 20.
24. The immunogenic peptide, the nucleic acid, the expression cassette, the expression vector, the virus, the cell or the vaccine for use according to claim 23, wherein the first immunogenic peptide, nucleic acid, expression cassette, expression vector, virus, cell or vaccine are different from the second immunogenic peptide, nucleic acid, expression cassette, expression vector, virus, cell or vaccine.
25. The immunogenic peptide, the nucleic acid, the expression cassette, the expression vector, the virus, the cell or the vaccine for use according to claim 24, wherein it is administered an expression vector according to claim 16 followed by the administration of a Modified Vaccinia Ankara virus according to claim 18.
26. The immunogenic peptide, the nucleic acid, the expression cassette, the expression vector, the virus, the cell or the vaccine for use according to claim 25, wherein the expression vector according to claim 16 is administered at least twice.
27. A kit comprising the immunogen of any of claims 1-11, the nucleic acid of claims 12-14, the expression cassette of claim 15, the expression vector of claim 16, the virus of any of claims 17-18, the cell of claim 19 or the vaccine of claims 20.
PCT/EP2013/051596 2012-01-27 2013-01-28 Immunogens for hiv vaccination WO2013110818A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
ES13701288T ES2932407T3 (en) 2012-01-27 2013-01-28 Immunogens for vaccination against HIV
EP13701288.6A EP2807185B1 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
KR1020197018840A KR102140778B1 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
KR1020147023946A KR102108149B1 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
IN6164DEN2014 IN2014DN06164A (en) 2012-01-27 2013-01-28
JP2014553750A JP6306514B2 (en) 2012-01-27 2013-01-28 Immunogen for HIV vaccination
CA2862172A CA2862172C (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
EP22195110.6A EP4163290A1 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
AU2013213564A AU2013213564B2 (en) 2012-01-27 2013-01-28 Immunogens for HIV vaccination
CN201380006995.6A CN104080800B (en) 2012-01-27 2013-01-28 Immunogene for HIV vaccine inoculation
BR112014018396-1A BR112014018396B1 (en) 2012-01-27 2013-01-28 IMMUNOGENS FOR HIV VACCINATION
US14/374,334 US9988425B2 (en) 2012-01-27 2013-01-28 Immunogens for HIV vaccination
RU2014135053A RU2648791C2 (en) 2012-01-27 2013-01-28 Immunogens for vaccination against hiv
NZ628756A NZ628756A (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
MX2014009091A MX358711B (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination.
ZA2014/05204A ZA201405204B (en) 2012-01-27 2014-07-16 Immunogens for hiv vaccination
IL233771A IL233771B (en) 2012-01-27 2014-07-23 Immunogens for hiv vaccination
HK15105237.5A HK1204632A1 (en) 2012-01-27 2015-06-02 Immunogens for hiv vaccination hiv
US15/718,635 US10815278B2 (en) 2012-01-27 2017-09-28 Immunogens for HIV vaccination
US15/970,216 US11325946B2 (en) 2012-01-27 2018-05-03 Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising gag, pol, vif and nef epitopes
AU2018203264A AU2018203264B2 (en) 2012-01-27 2018-05-10 Immunogens for HIV vaccination
IL268629A IL268629B (en) 2012-01-27 2019-08-11 Immunogens for hiv vaccination
US17/244,042 US11919926B2 (en) 2012-01-27 2021-04-29 Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382031.8A EP2620446A1 (en) 2012-01-27 2012-01-27 Immunogens for HIV vaccination
EP12382031.8 2012-01-27

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/374,334 A-371-Of-International US9988425B2 (en) 2012-01-27 2013-01-28 Immunogens for HIV vaccination
US15/718,635 Continuation US10815278B2 (en) 2012-01-27 2017-09-28 Immunogens for HIV vaccination
US15/970,216 Division US11325946B2 (en) 2012-01-27 2018-05-03 Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising gag, pol, vif and nef epitopes

Publications (2)

Publication Number Publication Date
WO2013110818A2 true WO2013110818A2 (en) 2013-08-01
WO2013110818A3 WO2013110818A3 (en) 2013-11-07

Family

ID=47603800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/051596 WO2013110818A2 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Country Status (17)

Country Link
US (4) US9988425B2 (en)
EP (3) EP2620446A1 (en)
JP (2) JP6306514B2 (en)
KR (2) KR102108149B1 (en)
CN (2) CN104080800B (en)
AU (2) AU2013213564B2 (en)
BR (1) BR112014018396B1 (en)
CA (1) CA2862172C (en)
ES (1) ES2932407T3 (en)
HK (1) HK1204632A1 (en)
IL (2) IL233771B (en)
IN (1) IN2014DN06164A (en)
MX (2) MX358711B (en)
NZ (3) NZ628756A (en)
RU (2) RU2648791C2 (en)
WO (1) WO2013110818A2 (en)
ZA (1) ZA201405204B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007765A1 (en) 2014-07-11 2016-01-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2020237027A1 (en) 2019-05-22 2020-11-26 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
WO2020234839A1 (en) 2019-05-22 2020-11-26 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021228816A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
US11554168B2 (en) 2014-10-03 2023-01-17 Vir Biotechnology, Inc. HIV vaccines comprising one or more population episensus antigens

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
PT2364314E (en) 2008-12-09 2014-06-09 Gilead Sciences Inc Modulators of toll-like receptors
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CA2943478A1 (en) * 2014-03-21 2015-09-24 Nutech Ventures A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
BR102015023450A2 (en) 2014-09-16 2016-04-12 Gilead Sciences Inc solid forms of a toll-like receptor modulator
CN114761041A (en) 2019-07-16 2022-07-15 吉利德科学公司 HIV vaccines and methods of making and using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH568392A5 (en) 1971-09-11 1975-10-31 Bayern Freistaat
WO1996020013A1 (en) 1994-12-24 1996-07-04 Cambridge University Technical Services Limited Improvements in or relating to endometrial function
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1997028816A1 (en) 1996-02-09 1997-08-14 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US6440422B1 (en) 1995-07-04 2002-08-27 Gsf-Forschungszentrum Fur Umwelt Und Gesenudheit Gmbh Recombinant MVA virus, and the use thereof
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858712B1 (en) 1984-08-22 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en) 1992-09-16 2008-01-15 Board Of Regents, The University Of Texas System Compositions and methods for eliciting immune or anti-infective responses
AU693098B2 (en) 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
CN1233187A (en) 1996-08-09 1999-10-27 病毒技术公司 HIVp-17 peptide fragment, compositions containing and methods for producing and using same
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
US6031647A (en) 1996-10-23 2000-02-29 Nortel Networks Corporation Stable power control for optical transmission systems
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
CN1297932A (en) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 Human lipoprotein precursor protein signal peptidell as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1213068C (en) 1999-12-23 2005-08-03 医疗研究局 Improvments in or relating to immune responses to HIV
FR2803307A1 (en) 1999-12-30 2001-07-06 Centre Nat Rech Scient SPECIFIC TH1 TYPE CD4 T LYMPHOCYTES LINES AND METHOD FOR THEIR EX VIVO INDUCTION
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1312275A (en) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 Human heat shock protein 15 as one new polypeptide and polynucleotides encoding this polypeptide
JP2003531865A (en) 2000-04-28 2003-10-28 アメリカ合衆国 Improving immunogenicity using a combination of DNA and vaccinia virus vector vaccines
ATE318908T1 (en) 2000-05-18 2006-03-15 Geneart Gmbh SYNTHETIC GENES FOR GAGPOL AND THEIR USES
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
EP1311686A2 (en) * 2000-08-14 2003-05-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
CU23235A1 (en) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech RECOMBINANT POXVIRUS FOR CHEMICAL PROTEINS OF THE HUMAN IMMUNODEFICIENCY VIRUS AND ITS APPLICATION IN THERAPEUTICS AND AIDS PREVENTION
US20070015721A1 (en) 2001-09-20 2007-01-18 Andrew Beaton Hiv-gag codon-optimised dna vaccines
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
EP1487486B1 (en) 2002-03-19 2009-01-14 PowderJect Research Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
RU2238946C2 (en) * 2002-04-22 2004-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Artificial protein-immunogen tci comprising multiple ctl-epitopes of hiv-1 basic antigens, artificial gene tci encoding polyepitope protein-immunogen tci
NZ536499A (en) 2002-05-16 2008-04-30 Bavarian Nordic As Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini
US7338662B2 (en) 2002-05-16 2008-03-04 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the foxviral genome
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003245729A1 (en) 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne Immunomodulating compositions, uses therefor and processes for their production
JP4773352B2 (en) 2003-09-17 2011-09-14 デューク ユニバーシティ Consensus / ancestral immunogen
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory Improved mva vaccines
JP2007534302A (en) 2003-09-24 2007-11-29 オクソン セラピュティクス リミテッド HIV medicine
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
WO2005047483A2 (en) 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
WO2006010106A2 (en) * 2004-07-09 2006-01-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Dna-based vaccination of retroviral-infected individuals undergoing treatment
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US9453239B2 (en) 2004-08-27 2016-09-27 Emory University Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en) 2004-10-29 2006-07-20 Microsoft Corporation Association-based epitome design
WO2006123256A2 (en) 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
AU2006268333B2 (en) * 2005-07-11 2012-06-14 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
BRPI0504117A (en) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epitopes, combination of epitopes, uses of epitopes or their combination, composition, uses of composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for identifying epitopes and methods for treatment or prevention.
CA2645342A1 (en) 2006-03-10 2007-09-20 Peptcell Limited Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
CA2670804A1 (en) 2006-05-19 2007-11-29 Sanofi Pasteur Inc. Immunological composition
WO2008142479A2 (en) 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
US8198082B2 (en) 2007-03-28 2012-06-12 Hiroshima University Method of determining chicken embryonic stem cells
EP2147121B1 (en) * 2007-04-26 2014-12-17 Merck Sharp & Dohme Corp. Synthetic expression vectors for insect cells
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
AU2008348260A1 (en) 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
EP2307048A4 (en) * 2008-07-16 2012-02-29 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef to dendritic cells
US8709775B2 (en) 2008-08-29 2014-04-29 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US9017691B2 (en) * 2008-11-18 2015-04-28 Beth Israel Deaconess Medical Center Antiviral vaccines with improved cellular immunogenicity
EP2477651A1 (en) 2009-09-17 2012-07-25 Sanofi Pasteur Inc. Immunological compositions for hiv
WO2011042180A1 (en) * 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
CA2777744C (en) 2009-10-16 2019-09-24 Bernard Moss Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
EP2521733A4 (en) 2010-01-04 2013-07-10 August Thomas Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
KR20220011685A (en) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Combination of a TLR7 modulating compound with an HIV vaccine
CN114828884A (en) 2019-05-22 2022-07-29 埃利克斯疗法公司 Dosage regimen for vaccines
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH568392A5 (en) 1971-09-11 1975-10-31 Bayern Freistaat
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1996020013A1 (en) 1994-12-24 1996-07-04 Cambridge University Technical Services Limited Improvements in or relating to endometrial function
US6440422B1 (en) 1995-07-04 2002-08-27 Gsf-Forschungszentrum Fur Umwelt Und Gesenudheit Gmbh Recombinant MVA virus, and the use thereof
WO1997028816A1 (en) 1996-02-09 1997-08-14 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant

Non-Patent Citations (56)

* Cited by examiner, † Cited by third party
Title
ADLER M ET AL., BRIT. MED. J., vol. 294, 1987, pages 1145 - 1147
ALTMAN J ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10330 - 10334
ALTMAN J ET AL., SCIENCE, vol. 274, 1996, pages 94 - 96
ALTSCHUL S ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL S ET AL., NUC. ACIDS RES., vol. 25, 1977, pages 3389 - 3402
ANDRE S ET AL., J. VIROL., vol. 72, 1998, pages 1497 - 1503
AUER H, NATURE BIOTECHNOL., vol. 24, 2006, pages 41 - 43
BETTS M ET AL., J. IMMUNOL. METHODS, vol. 281, 2003, pages 65 - 78
BRANDER C ET AL., CURRENT OPINION IMMUNOL., vol. 18, 2006, pages 1 - 8
BROCKMAN M ET AL., J. VIROL., vol. 81, 2007, pages 12608 - 12618
BROWN T: "Gene Cloning", 1995, CHAPMAN & HALL
BURKE S ET AL., J. INF. DIS., vol. 170, 1994, pages 1110 - 1119
CHATTOPADHYAY P ET AL., NAT. MED., vol. 11, 2005, pages 1113 - 11117
DAVIS H ET AL., HUM. MOL. GEN., vol. 2, 1993, pages 1847 - 1851
DAVIS H ET AL., VACCINE, vol. 12, 1994, pages 1503 - 1509
FENG L ET AL., BIOCHEMISTRY, vol. 39, no. 50, 2000, pages 15399 - 15409
FRAHM N ET AL., J. VIROL., vol. 78, 2004, pages 2187 - 2200
FRAHM N ET AL., NAT. IMMUNOL., vol. 7, 2006, pages 173 - 178
FRENTSCH M ET AL., NAT. MED., vol. 11, 2005, pages 1118 - 1124
FRIEDRICH T ET AL., J. VIROL., vol. 81, 2007, pages 3465 - 3476
GENNARO A,: "Remington's Pharmaceutical Sciences, 18th Ed.", 1990, MACK PUBLISHING CO.
HARLOW E; LANE D: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR
HOFFMAN S ET AL., VACCINE, vol. 12, no. 16, 1994, pages 1529 - 1533
HONEYBORNE I ET AL., J. VIROL., vol. 81, 2007, pages 3667 - 3672
HUMPHREYS D ET AL., PROTEIN EXPR. PURIF., vol. 20, no. 2, 2000, pages 252 - 2
JOHNSON V ET AL., ISA-USA TOPICS ANTIVIRAL MED., vol. 19, no. 4, 2011, pages 153 - 164
JOHNSTON S ET AL., METH. CELL BIOL., vol. 43, 1994, pages 353 - 365
KIEPIELA P ET AL., NAT. MED., vol. 13, 2007, pages 46 - 53
KIEPIELA P ET AL., NATURE, vol. 432, 2004, pages 769 - 775
LESLIE A ET AL., NAT. MED., vol. 10, 2004, pages 282 - 289
MANNERING S ET AL., J. IMMUNOL. METHODS, vol. 283, 2003, pages 173 - 183
MAYR A ET AL., INFECTION, vol. 3, 1975, pages 6 - 14
MOTHE B ET AL., J. TRANSL. MED., vol. 9, no. 1, 2011, pages 208
NARUM D ET AL., INFECT. IMMUN., vol. 69, no. 12, 2001, pages 7250 - 7253
NGUMBELA K ET AL., AIDS RES. HUM. RETROVIRUSES, vol. 24, 2008, pages 72 - 82
NICKLE D ET AL., SCIENCE, vol. 299, 2003, pages 1515 - 1517
NOVAK E ET AL., J. CLIN. INVEST., vol. 104, 1999, pages R63 - R67
OSOL A.,: "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO., pages: 1324 - 1341
OUTCHKOUROV N ET AL., PROTEIN EXPR. PURIF., vol. 24, no. 1, 2002, pages 18 - 24
ROBINSON H ET AL., VACCINE, vol. 11, 1993, pages 957 - 960
ROSATI M ET AL., PROC. NATL. ACAD. SCI. USA, vol. 106, 2009, pages 15831 - 15836
SAMBROOK ET AL.: "Molecular Cloning. A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR
SCHNEIDEWIND A ET AL., J. VIROL., vol. 81, 2007, pages 12382 - 12393
SCHWARTZ S ET AL., J. VIROL., vol. 66, no. 12, 1992, pages 7176 - 7182
SHAFER R ET AL., AIDS REV., vol. 0, no. 2, 2008, pages 67 - 84
SHAFER R ET AL., AIDS REV., vol. 10, no. 2, 2008, pages 67 - 84
SHAFER R: "Assay for Antiretroviral Resistance", HIV INSITE KNOWLEDGE BASE CHAPTER, January 2012 (2012-01-01), Retrieved from the Internet <URL:http://hivinsite.ucsfedu/InSite?page=kb-02-02-03>
TERPE K ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 60, 2003, pages 523 - 525
TIGGES M ET AL., J. IMMUNOL, vol. 156, 1996, pages 3901 - 3910
VOLLER A, ET AL.,: "New Trends and Developments in Vaccines", 1978, UNIVERSITY PARK PRESS
WATANABE M ET AL., MOL. REPROD. DEV., vol. 38, 1994, pages 268 - 274
WATSON R ET AL.: "Recombinant DNA, 2nd Ed.", 1992, SCIENTIFIC AMERICAN BOOKS
WEBSTER R ET AL., VACCINE, vol. 12, 1994, pages 1495 - 1498
XIANG Z ET AL., VIROLOGY, vol. 199, 1994, pages 132 - 140
YERLY D ET AL., J. VIROL., vol. 82, 2008, pages 3147 - 3153
ZUNIGA R ET AL., J. VIROL., vol. 80, 2006, pages 3122 - 3125

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007765A1 (en) 2014-07-11 2016-01-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
US11554168B2 (en) 2014-10-03 2023-01-17 Vir Biotechnology, Inc. HIV vaccines comprising one or more population episensus antigens
US11628215B2 (en) 2014-10-03 2023-04-18 Vir Biotechnology, Inc. HIV vaccines comprising one or more population episensus antigens
WO2020237027A1 (en) 2019-05-22 2020-11-26 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
WO2020234839A1 (en) 2019-05-22 2020-11-26 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
US11666651B2 (en) 2019-11-14 2023-06-06 Aelix Therapeutics, S.L. Prime/boost immunization regimen against HIV-1 utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
WO2021228816A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens

Also Published As

Publication number Publication date
AU2018203264B2 (en) 2019-07-11
EP2807185A2 (en) 2014-12-03
US9988425B2 (en) 2018-06-05
KR20190085552A (en) 2019-07-18
MX2018010483A (en) 2020-09-02
KR102140778B1 (en) 2020-08-06
WO2013110818A3 (en) 2013-11-07
IL268629B (en) 2021-06-30
ZA201405204B (en) 2015-10-28
NZ628756A (en) 2016-12-23
MX358711B (en) 2018-08-31
EP2807185B1 (en) 2022-09-14
EP4163290A1 (en) 2023-04-12
CN104080800B (en) 2019-08-27
AU2018203264A1 (en) 2018-05-31
RU2721274C2 (en) 2020-05-18
CA2862172A1 (en) 2013-08-01
RU2648791C2 (en) 2018-04-02
US11919926B2 (en) 2024-03-05
HK1204632A1 (en) 2015-11-27
JP2015509707A (en) 2015-04-02
BR112014018396A8 (en) 2017-07-11
RU2014135053A (en) 2016-03-27
ES2932407T3 (en) 2023-01-18
US20180170971A1 (en) 2018-06-21
KR102108149B1 (en) 2020-05-12
JP6749357B2 (en) 2020-09-02
KR20140122735A (en) 2014-10-20
RU2018104969A (en) 2019-02-22
JP6306514B2 (en) 2018-04-04
RU2018104969A3 (en) 2019-02-22
EP2620446A1 (en) 2013-07-31
IN2014DN06164A (en) 2015-08-21
IL233771B (en) 2019-08-29
IL233771A0 (en) 2014-09-30
US20190055289A1 (en) 2019-02-21
NZ734689A (en) 2022-09-30
US10815278B2 (en) 2020-10-27
AU2013213564B2 (en) 2018-03-29
AU2013213564A1 (en) 2014-09-04
US20210246172A1 (en) 2021-08-12
CN104080800A (en) 2014-10-01
NZ723229A (en) 2019-03-29
CN110372798A (en) 2019-10-25
CA2862172C (en) 2023-07-18
US11325946B2 (en) 2022-05-10
BR112014018396A2 (en) 2017-06-20
MX2014009091A (en) 2014-11-10
BR112014018396B1 (en) 2023-03-21
IL268629A (en) 2019-10-31
JP2018102314A (en) 2018-07-05
US20150050310A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
US11919926B2 (en) Method of treating HIV-1 infection utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
AU762893B2 (en) HIV-1 Tat, or derivatives thereof for prophylactic and therapeutic vaccination
Rasmussen et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus
AU784635B2 (en) The genome of the HIV-1 inter-subtype (C/B&#39;) and use thereof
WO2005039631A1 (en) Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses
CA2489292A1 (en) Vectors for expression of hml-2 polypeptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13701288

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2862172

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 233771

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 14374334

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014553750

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/009091

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014018396

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20147023946

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2014135053

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013701288

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013213564

Country of ref document: AU

Date of ref document: 20130128

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112014018396

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140725